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 CHAPTER I
Introduction
CHAPTER I  1 
 
 
 
Intestinal Immunity 
 
Intestinal immunity is a relatively new term in relation to events and processes that 
regard human biology. Microorganisms inhabited the earth long before humans. The 
evolution of intestinal immunity was therefore influenced by its interaction with these 
microorganisms. The intestinal tract successfully handles the situation in a way better 
than any other defense system. It encounters an enormous load of antigens while 
maintaining a normal homeostatic environment. Most of these antigens are beneficial to 
the host, such as dietary antigens and symbiotic bacteria, and some are harmless, such as 
commensals. On the other hand, pathogenic microorganisms need to be recognized and 
eliminated before damage occurs. Whereas the systemic immune system elicits an 
aggressive immune response to exposure of any nonself antigens, the intestinal immune 
system needs to be more flexible. Antigens need to be sampled, processed, and 
presented in such a way that enables the elimination of pathogens and tolerance to 
nonpathogens. Therefore, the rules governing intestinal immunity differ from those 
observed in systemic immunity. The challenge of facing billions of bacteria, limitless 
dietary antigens, and the largest pool of lymphocytes in the body necessitated the 
development of unique cells, mediator, and regulatory processes. Cells of the gut-
associated lymphoid tissue (GALT) include conventional cells of the innate and 
adaptive immune system such as B and T lymphocytes, macrophages and dendritic cells 
(DC), as well as non classical antigen-presenting cells (APC), such as intestinal 
epithelial cells (IEC), and finally the lymphocytes specific for the GALT, lamina propria 
lymphocytes (LPL) and intestinal epithelial lymphocytes (IEL). As consequence of their 
antigen-exposed environment, these cells have unique activation requirements, they 
secrete and are influenced by a special array of cytokines and mediators. 
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1 Gastrointestinal immune system 
1.1 Barrier and unspecific defense mechanisms 
The intestinal mucosa is the interface between the immune system and the massive 
antigenic load represented by the commensal and potentially pathogenic enteric bacteria 
(Hooper et al., 1998). A variety of mechanisms contribute to the ability of the gut to 
either react or remain tolerant to antigen present in the intestinal lumen. The epithelial 
cell layer forms a barrier against exposure to mucosal microflora and other mucosal 
antigens and thus plays a key role in regulation of mucosal immune responses. Crucial 
for an efficient barrier function are specialized adaptations of the intestine, including 
mucus secretion, tight junctions between epithelial cells, defensins and immunoglobulin 
(Ig) A. Mucus is produced as a thick layer along the intestinal membrane. The functions 
of these large-molecular-weight glycoproteins are multifold: trapping bacteria and 
viruses, preventing them from gaining initial access to the host and serving as a 
microenvironment for the accumulation of bacteriocidal and bacteriostatic chemical 
enzymes. Intestinal epithelial cells (IEC) form intercellular tight junctions that 
effectively restrict transepithelial movement of particulate and even hydrophilic 
molecules of molecular mass higher than 2.000 Da, thus preventing uncontrolled uptake 
of bacteria and many of their metabolites (Madara et al., 1992). However, the defense 
function of the intestinal epithelium is not limited to providing a barrier. Rather, the 
intestinal epithelium actively interacts with both microbes and immune cells via the 
secretion of cellular immune mediators. A specialized form of peptides secreted by IEC 
are defensins and trefoil peptides which exhibit direct antimicrobial activity (Ayabe et 
al., 2002; Wong et al., 1999). In addition, the intestinal epithelium transports products of 
bacteria and immune cells. For example, it has long been known that immunoglobulin A 
(IgA) produced by B cells is transcytosed by IEC into the intestinal lumen and that this 
IgA is protective for the host via neutralization of important molecules on the bacterial 
surface or binding and elimination of bacteria that already invaded the epithelium 
(Robinson et al., 2001). 
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1.2 The inductive sites for mucosal immune responses 
1.2.1 Peyers’s patches and M cells 
Peyer’s patches are macroscopic lymphoid aggregates that are located in the submucosa 
along the length of the small intestine. Mature Peyer’s patches consist of collections of 
large B cell follicles and intervening T cell areas. The lymphoid areas are separated 
from the intestinal lumen by a single layer of columnar epithelial cells, known as the 
follicle-associated epithelium (FAE), and a more diffuse area immediately below the 
epithelium, known as the subepithelial dome (SED).  
 
 
Figure 1: Inductive sites of the 
GALT. The GALT is the major 
inductive site of the gastrointestinal
tract. The Payer’s patches of the 
GALT consist of a follicle-
associated epithelium with 
specialized M cells, a subepithelial 
dome overlying follicles, and 
interfollicular regions enriched in T 
cells (adapted from Neurath et al., 
2002). 
 
 
 
 
The FAE differs from the epithelium that covers the villus mucosa, as it has lower levels 
of digestive enzymes and a less pronounced brush border. The brush border is the 
surface layer of the normal small intestine that is comprised of small microvilli coated in 
a rich glycocalyx of mucus and other glycoproteins. Microvilli contain many of the 
digestive enzymes and transporter systems that are involved in the metabolism and 
uptake of dietary material. The brush border provides a large surface area for absorption. 
The FAE is infiltrated by large numbers of B cells, T cells, macrophages and dendritic 
cells and the most notable feature of the FAE is the presence of microfold (M) cells, 
which are specialized enterocytes that lack surface microvilli and the normal thick layer 
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of mucus. Uptake and presentation of antigens to naïve T and B cells to induce an 
adequate immune response is the primary function of the M cells in the mucosa.  
Following ingestion, antigens and microorganisms are transported from the gut lumen to 
the dome region through these specialized M cells. Here they encounter APCs such as 
DCs leading to cognate interactions between APCs and T cells. DCs can also migrate to 
the interfollicular regions enriched with T cells and containing high endothelial venules 
(HEV) and efferent lymphatics to initiate an immune response upon antigen uptake. 
 
 
 
 
 
Following induction in the GALT, mature lymph
migrate to the effector sides such as the lamina 
inflammatory as well as suppressive immune resp
signals cytokines produced by mucosal TH1 an
regulatory role.  
 
 Figure 2: Immune response in the 
intestine. Antigens can be presented to T 
cells by DCs. In the normal gut immune 
system, immature DCs seem to 
preferentially induce Treg and TH3 T cell 
responses. In the presence of cytokines 
such as IL-12 and IFN-α produced by 
CD8α+ DCs, T cells can differentiate into 
TH1 effector cells, whereas IL-4 can induce 
TH2 T cell differentiation. TH1 cells 
express the IL-12 receptor β2 chain and the 
IL-18 receptor, TH2 cells express an IL-1-
like molecule that appears to regulate TH2 
effector functions both in the peripheral
and the mucosal immune system (adapted 
from Neurath et al., 2002). 
 ocytes leave the inductive sides and 
propria where they can induce pro-
onses. Among the pro-inflammatory 
d TH2 effector cells have a central 
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1.3 The effector sites for mucosal immune responses 
1.3.1 Intestinal epithelial cells (IEC) 
Besides of professional antigen presenting cells like DCs, macrophages and B cells, 
non-professional antigen presenting cells exist in the intestine. Epithelial cells of the 
GALT play an important role as accessory cells in both B and T cell mucosal immune 
functions. Whereas their role in B cell mediated immunity, which is the transport of IgA 
synthesized by plasma cells in the lamina propria to the mucosal surface, is well 
characterized (Mestecky & Russell, 1991), the role of epithelial cells in mucosal T cell 
function is not yet fully understood. Since the 1980’s it became clear that IEC express 
several surface molecules that are involved in antigen presentation, such as MHC 
molecules, CD1d or CD86. However, in contrast to professional APC, IEC are not 
equipped with the complete setting of antigen-presenting and costimulatory molecules. 
Therefore, they might be able of providing lymphocytes with the TCR stimulatory 
signal without costimulation, a situation normally resulting in anergy rather than T cell 
activation (Chen at al., 1995). It is well established that most of the LPL, as well as the 
IEL, are memory cells requiring less or even no costimulation to get activated. More 
important, it was discovered that in addition to classical MHC class I and II molecules, 
IEC express several unique costimulatory molecules either constitutively or during 
inflammation. Under normal conditions IEC do not express B7-1, B7-2 or CD40, but do 
express LFA-3 (Framson et al., 1999) and gp180 (Yio & Mayer 1997). In contrast, in 
inflammatory bowel disease IEC are induced to express B7-2 as well as infected IEC do 
express intercellular adhesion molecule-1 (ICAM-1) (Huang et al., 1996). Taken 
together, the localization of IEC separating antigens from lymphocytes, the expression 
of surface molecules required for lymphocyte activation and costimulation, and the 
ability to interact with LPL as well as IEL make the IEC a prime candidate for antigen 
presentation in the mucosal immune system.  
For the interaction of IEC with T cells, Dotan & Mayer (Fig. 3) developed a model 
suggesting that luminal antigens derived from food or bacteria may be internalized via 
the apical epithelial surface (Dotan & Mayer, 2003). During  inflammatory processes, 
paracellular transport of antigens and presentation by basolateral surface molecules 
occurs. The amount and type of antigen, as well as the combination of antigen-
presenting molecules with costimulatory molecules determines the population of T cells 
that will expand. CD8+ IEL and LPL may be stimulated by classical MHC class I 
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molecules. Stimulation by class I-like molecules, such as the complex gp180:CD1d and 
MICA/MICB, may also occur. Here, the antigen presented in the IEC:CD8+ T cell 
interaction is of nonpeptide origin.  
 
 
 
 
 
 
 
 
 
Figure 3: The interaction of IEC with T cells. IEC express a variety of surface molecules relevant 
for antigen presentation and stimulation of T cells. Luminal antigens derived from food or bacteria 
may be internalized via the apical surface. In the presence of inflammation, paracellular transport of 
antigens and presentation by basolateral surface molecules occur. The amount and type of antigen, as 
well as the combination of antigen-presenting molecules with costimulatory molecules, determine the
population of T cells that will expand (adapted from Dotan & Mayer, 2003). 
 
 
When presented by CD1d, data suggested bacterial-derived phospholipids as antigens. 
CD8+ T cells activated by IEC have a suppressor activity and may function in regulating 
mucosal homeostasis. Peptide antigens can be presented to CD4+ T cells by MHC class 
II molecules, which are constitutively expressed on IEC. Different CD4+ T cell 
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populations may expand when the antigen is taken up via the apical or the basolateral 
surface. In normal mucosal homeostasis, regulatory CD4+ T cells, activated via MHC 
class II without costimulation, may contribute to controlled inflammation. In 
inflammatory states, up-regulation of MHC class II as well as costimulatory molecules 
such as B7-2 on IEC may promote the expansion of TH1/TH2 cells and contribute to 
uncontrolled inflammation.  
 
1.3.2 Chemokine/Cytokine secretion by IEC 
The IEC show a variety of functions in mucosal immune homeostasis. Their functions 
as barrier between the antigenic load and the mucosal immune system and as a 
nonprofessional APC have described in paragraph 1.1 and 1.3.1. In addition, IEC secrete 
mediators that influence cells in their vicinity. Several chemokines and cytokines have 
recently been shown to be expressed by IEC. IEC-derived chemokines can induce the 
migration of inflammatory cells towards the epithelium. Therefore, their production by 
IEC demonstrate the potential for active participation in intestinal innate and adaptive 
immune responses. 
The main chemokines produced by IEC are CXC chemokines, monokine induced by 
IFN-γ (MIG), IFN-γ inducible protein 10 (IP-10), and interferon-inducible T-cell α-
chemoattractant (I-TAC) (Dwinel et al., 2001; Shibahara et al., 2001). The receptors of 
these chemokines are expressed on IEL indicating a strong correlation between IEC and 
migration of IEL into the epithelium. A CC chemokine that attracts immature DCs, 
macrophage inflammatory protein-3α (MIP-3α), is also produced by IEC (Neutra et al., 
2001). Besides chemokines, IEC produce cytokines like IL-7 and IL-15, cytokines with 
growth factor activity for γδTCR+ and CD8+ T cells in the mucosa (Reinecker & 
Podolsky, 1995). Additionally, cytokines typically expressed by IEC are TGF-α and -β, 
IL-6, TNF-α, and IL-10 (Podolsky, 1997; Taylor et al., 1998; Hogan et al., 2001). 
Furthermore, the IEC express the receptors for these cytokines, which therefore seem to 
be involved in autocrine activation pathways of IEC. 
 
1.3.3 Lymphocytes in the GALT 
As mentioned above, two distinct lymphocyte populations do exist in the GALT, 
namely the intraepithelial lymphocytes and lamina propria lymphocytes which are 
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separated by the thin basement membrane between the epithelium and the Lamina 
propia. Both are different from systemic lymphocytes with regard to phenotype and 
activation requirements, also there are differences between those two population with 
respect to phenotype, function and cytokine secretion. 
1.3.3.1 Intraepithelial lymphocytes (IEL) 
IEL are among the most intriguing lymphocytes that exist. It is surprising that despite 
their numbers (epithelial lymphocytes are one of the major lymphocyte populations in 
the body) and the fact that they are the focus of intense research, their function is as yet 
poorly defined. This is attributed in part to difficulties in their isolation and to the 
intrinsic heterogeneity of IEL subsets. Virtually all IEL are T cells, most of which are 
CD8+ (~ 70 %), at least in the small bowel. In contrast to their systemic counterparts, the 
majority of CD8+ IEL in young mice expresses the CD8αα homodimer. Two 
phenotypes that are rare in circulation are existing in the IEL population: CD4-CD8- 
double negative (~ 10 %) and CD4+CD8αα+ (5-10 %) T cells. Another unique 
characteristic of IEL is their TCR usage, either αβ or γδ. Since different TCR 
phenotypes are associated with different functional characteristics, Hayday et al. (2001) 
suggested a classification of type a and type b IEL, to simplify characterization. 
According to this classification, type a IEL are TCRαβ+ CD8αβ+ and their proportion in 
the human small and large intestine is between 50 % and 100 %, respectively. Type a 
IEL are cytolytic cells with an oligoclonal repertoire that partially overlaps that of the 
lamina propria and thoracic duct CD8+ T cells. This observations supports the 
hypothesis that type a IEL are primed in the mucosal-associated lymphoid tissue 
(MALT), migrate via the MLN and the thoracic duct to systemic circulation, and home 
back to the LP, from where they pass into the epithelium. In this regard, they express the 
integrin α4β7, which binds to the mucosal addressin MAdCAM-1. Homing is also 
directed by chemokines expressed by the IEC such as IP-10, MIG and I-TAC (Dwinel et 
al., 2001; Shibahara et al., 2001). IEL express CXCR3, the cognate receptor for these 
chemokines, as well as CCR9, the receptor for TECK that is expressed in small bowel 
IEC (Zabel et al., 1999). Furthermore, almost all IEL express αΕβ7. This integrin binds 
to E-cadherin on IEC and may lead to the accumulation of IEL within the epithelium.  
Type b IEL are TCRαβ+ CD8αα+, TCRγδ CD8αα+, and TCRγδ “double negative” T 
cells. They show a different gene expression for T cell maturation markers, as failing to 
express CD2, CD28 and CD5 (reviewed in Hayday et al., 2001). They differ also by 
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MHC restriction, as type a IEL being conventionally restricted while type b IEL do not 
react in a classical way to their specific antigen in the MHC restriction element. Type b 
IEL are less MHC dependent and may develop in athymic mice, leading to the 
hypothesis that these cells may be auto-reactive, regulatory cells positively selected in 
the periphery. Current data suggested that type b IEL may have a role in promoting 
epithelial repair and healing as well as in eliminating infected or transformed epithelial 
cells. 
1.3.3.2 Lamina propria lymphocytes (LPL) 
Another lymphocyte population of the intestinal immune system resides in the lamina 
propria. LPL are a very heterogeneous group of T and B cells. In contrast to IEL, the LP 
CD4:CD8 T cell ratio is similar to that in the blood, and they express the αβTCR. 
Similar to IEL, most of the LPL are memory cells exhibiting an activated phenotype. 
Interestingly, when stimulated via the TCR their responses are poor, and they seem to 
depend on CD2/CD28-mediated stimulation to proliferate and secrete cytokines 
(Boirivant et al., 1999; Targan et al., 1995). The propensity for stimulation via the CD2 
pathway may be one explanation for the increased tendency towards apoptotic cell death 
in comparison to peripheral blood lymphocytes. The increased susceptibility to 
apoptosis may be related to the fact that the vast majority of LPL express FAS antigen 
and a subset also FAS ligand (DeMaria et al., 1996). Not only more LPL than their 
peripheral counterparts are FAS positive, also upon FAS ligation, cell death is induced 
more effectively in LPL, suggesting that they are “death prone” (DeMaria et al., 1996). 
The significance of LPL preprogrammed cell death for intestinal homeostasis is seen in 
conditions in which this homeostasis is disturbed. In inflammatory bowel disease, 
mucosal inflammation is associated with decreased sensitivity of LPL to cell death 
induced by FAS ligation or by other cell-death inducers such as deprivation of IL-2 and 
exposure to nitric oxide. Differences between normal LPL and those isolated from 
inflamed mucosa show that apoptosis-associated genes such as bax and bcl-2 are 
differentially expressed in normal versus inflamed mucosa. Specifically, increased 
expression of the anti-apoptitic BCL-2 protein, increased Bcl/Bax ratio in the mucosa, 
and decreased Bax expression in LPL were reported in Crohn’s disease (Ina et al. 1999.; 
Itoh et al., 2001). This suggests that normal LPL represent an activated, apoptosis-prone 
population and that dysregulation of the death propensity may leads to intestinal 
inflammation. There are inconsistent reports about the cytokine secretion of LPL. 
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However, it has been shown that IFN-γ is produced by LPL both in the normal state and 
in inflammatory conditions. Other cytokines produced under various conditions and 
stimuli are IL-5 in Ulcerative colitis and TNF-α in Crohn’s disease (Camoglio et al., 
1998; Fuss et al., 1996; Murch et al., 1993; Reinecker et al., 1993; Samoilova et al., 
1998). The targets for these cytokines are other immune cells like CD4+ T cells and 
macrophages, the IEC themselves, and even endothelial cells. A cytokine network is 
thus created in which activated LPL activate additional cells in the LP, thereby 
regulating or dysregulating mucosal homeostasis. 
 
1.3.4 Cytokine regulation of the mucosal immune response via mucosal T cells 
The differentiation into different T helper cell (TH) and T regulatory (Treg) cell cytokine 
response is a reasonable framework for describing the immune reactivity of systemic 
lymphoid tissues. Antigens, such as those derived from the microbial flora of the gut, 
are continuously sampled by M cells of the Peyer’s patches. The antigens are interpreted 
by APC which direct the differentiation of naïve CD4+ TH0 cells to one of several states 
of polarized cytokine production under the influence of cytokines and their associated 
signaling pathways (Fig. 4). 
TH1 cells secrete pro-inflammatory cytokines such as IFN-γ, IL-2, and TNF-α; TH2 cells 
secrete IL-4, IL-5, IL-6, IL-10 and IL-13, and promote IgA expression and other 
immunoglobulin isotypes. TH3 cells secrete TGF-β and Treg cells predominantly produce 
IL-10. Many of the functions of T cells in the gastrointestinal immune system are 
mediated by secreted cytokines. Recently, it has been shown that lamina propria T cells 
are producing higher levels of IL-10 compared to peripheral blood lymphocytes 
(Braunstein et al., 1997; Autschbach et al., 1998). It seems that IL-10 secreting 
regulatory T cells inhibit TH1 activation and that IL-10 produced in the intestine acts on 
macrophages to prevent their activation and the induction of pro-inflammatory 
cytokines, thereby inhibiting the recruitment of T cells to the intestine. It has also been 
shown that regulatory T cells, induced by oral antigen uptake, have characteristics of 
TH2 or TH3 cells (Weiner, 1997; Strobel & Mowat, 1998). On the other hand, it has been 
demonstrated in a TCR transgenic mouse model that continuous feeding of low dose 
antigen induces a TH1 cytokine response (Marth et al., 2000). In contrast, recent data 
revealed that TH1 cytokine production may not only have a pro-inflammatory effect as it 
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also can be protective in the immune regulation of certain infectious or autoimmune 
diseases (Dalton et al., 2000). 
 
 
 
 
  
 
 
 
Figure 4: Antigen uptake and recognition by CD4+ T cells in the intestine. Antigen might pass the 
epithelium through the M cells and after transfer to local DCs, might than be presented directly to naïve TH0 
cells, which directs the differentiation of the naïve TH0 cells into one of several state of polarized cytokine 
production under the influence of cytokines and their associated intracellular pathways. Under normal 
conditions, a balance is established between generation of pro-inflammatory TH1/TH2 and anti-inflammatory 
Tr1/TH3 cells. These activated cells spread widely via the lymphatic system to the lamina propria and the 
epithelium of the intestine. IL, interleukin; NFκB, Nuclear factor kappa B; IFN, interferon; TGF, tumor 
growth factor; Tr1; regulatory; STAT, signal transducer and activator of transcription (adapted from
Blumberg & Strober, 2001).  
CHAPTER I  12 
In addition to TCR stimulation by MHC/peptide/TCR crosslinking, T cells require a 
second signal in form of costimulation for complete activation. In the lymphoid system, 
denditric cells express high levels of costimulatory molecules, and these are up-
regulated upon maturation. In the healthy mucosa, lamina propria antigen-presenting 
cells provide only low levels of costimulatory signals (Qiao et al., 1996), but this second 
signal is up-regulated in inflammatory bowel disease (Rogler et al., 1999). Several 
reports suggest that the level and type of costimulation influences the naïve CD4+ TH0 
cell to develop a TH1 or TH2 phenotype. The costimulatory molecule involved in this 
processes are e.g. CD40, CD40L, CD44v7 or B7-1/2 (Wittig et al., 2000, 1998, 1999; 
Kuchroo et al., 1995; Rulifson et al., 1997). However, it will be important to determine 
whether differences in the expression of costimulatory molecules in mucosal inductive 
sites regulate the intestinal immune response to mucosal antigens. 
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2 Intestinal micoflora  
 
The gut is the natural habitat for a very diverse and dynamic bacterial community. The 
relevance and effect of resident bacteria on the host’s physiology and pathology has 
been well documented. Many species of bacteria have evolved and adapted to live and 
grow in the intestine. The intestinal habitat of an individual contains 300 - 500 different 
species of bacteria (Simon&Gorbach, 1984; Borriello, 1986) and the number of 
microbial cells within the gut lumen is about 10 times higher than the number of 
eukaryotic cells in the human body (Bengmark, 1998). Several hundred grams of 
bacteria living within the gut lumen affect the host immune homeostasis. Some of these 
bacteria are pathogenic and can be a source of infection and sepsis under certain 
circumstances - for example if the integrity of the intestinal barrier is physically or 
functionally broken. However, the constant interaction between the host and its 
microbial guest can infer important health benefits to the host (Salminen et al., 1998). 
 
2.1 Main functions of the microflora in health 
Use of animals bred under germ-free conditions has provided important information 
about the effect of the microbial community of the gut on host physiology and 
pathology (Falk et al., 1998). Such studies suggest that the microflora has important and 
specific metabolic, trophic and protective functions. 
 
A major metabolic function of the microflora is the fermentation of non-digestible 
dietary residue and endogenous mucus produced by epithelial cells (Roberfroid et al., 
1995). Gene diversity in the microbial community provides various enzymes and 
biochemical pathways that are distinct from the host’s own constitutive resources. 
Overall outcomes of this complex metabolic activity are recovery of metabolic energy 
and absorbable substrates for the host and in symbiosis supply of energy and nutritive 
products for bacterial growth and proliferation. The main topics of metabolic functions 
are in summary the salvage of energy as short-chain fatty acids, the production of 
vitamin K and the absorption of ions. 
 
Possibly the most important role of short-chain fatty acids on gut physiology is their 
trophic effect on the intestinal epithelium. The rate of production of crypt cells is 
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reduced in the colon of rats bred in germ-free environments, and their crypts contain 
fewer cells than those colonized by conventional flora, suggesting that intraluminal 
bacteria effect cell proliferation in the gut (Alam et al., 1994). Additionally, the 
differentiation of epithelial cells is greatly affected by interactions with resident bacteria 
(Hooper et al., 2001). All major short-chain fatty acids stimulate epithelial cell 
proliferation and differentiation in the large and small bowel in vivo (Frankel et al., 
1994). However, the microflora is not only important for the developing structure of the 
gut, as it has been shown that the interaction between gut and bacteria also influences 
the host immunity. The intestinal mucosa is the main interface between the immune 
system and the external environment. Thus, the gut-associated lymphoid tissue contains 
the largest pool of immunocompetent cells in the body (Brandzeag et al., 1989). The 
dialog between host and bacteria at the mucosal surface seems to play a part in 
development of a competent immune system. Animals bred in a germ-free environment 
have low densities of lymphoid cells in the gut mucosa, specialized follicle structures 
are small, and circulating concentration of immunoglobulin in the blood are low (Butler 
et al., 2000). Microbial colonization of the gastrointestinal tract affects the composition 
of gut-associated lymphoid tissue. Immediately after exposure to luminal microbes, the 
number of IEL expands greatly (Helgeland at al., 1996), germinal centers with 
immunoglobulin producing cells arise rapidly in follicles and the lamina propria (Cebra 
et al., 1998), and the concentration of immunoglobulin increases substantially in the 
serum (Butler et al., 2000). According to these results, the microflora is very necessary 
for the development of an intact, complete intestinal immune system. 
 
Resident bacteria are the crucial line of resistance to colonization by exogenous 
microbes and, therefore are highly relevant in prevention of invasion of tissue by 
pathogens. Germ-free animals are extraordinary susceptible to infections (Taguchi et al., 
2002). Several mechanisms have been implicated in the barrier effect. In vitro, bacteria 
compete for attachment sites in the brush border of intestinal epithelial cells (Bernet et 
al., 1994). Adherent non-pathogenic bacteria can prevent attachment and subsequent 
entry of pathogenic enteroinvasive bacteria into epithelial cells. Furthermore, bacteria 
can inhibit the growth of their competitors by producing antimicrobial substances 
(Brook, 1999; Lievin et al., 2000). However, resident bacteria are the first line of 
defense against exogenous pathogenic microbes. 
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2.2 Intestinal microflora in disease 
Besides all positive characteristics of intestinal bacteria, gut flora might also be an 
essential factor in certain pathological disorders, including inflammatory bowel disease 
(IBD). Resident bacterial flora has been suggested to be an important factor in driving 
the inflammatory processes in human inflammatory bowel disease (Shanahan, 2001). In 
patients with IBD, intestinal T lymphocytes are hyperreactive against bacterial antigens, 
and Pizer et al. (1991) suggested that local tolerance mechanisms are abrogated in such 
patients. Moreover, patients with IBD have higher amounts of bacteria attached to their 
epithelial surface than healthy people (Swidsinski et al., 2002). Thus, uncontrolled 
activation of the intestinal immune system by elements of the flora could be a key event 
in the pathophysiology of IBD. 
The idea that resident bacteria of the normal flora are involved in intestinal mucosal 
inflammation is supported by data from animal studies. Treatment with wide-spectrum 
antibiotics has been shown to mitigate mucosal inflammation in rats and mice with IBD 
(Videla et al., 1994). In general, experimental inflammation does not develop when mice 
are kept in germ-free environment (Sartor, 1997). The mucosal microflora is also 
required to initiate or maintain the inflammatory process, presumably by providing one 
or more antigens or costimulatory factors that drive the immune response in a 
genetically susceptible host. However, despite extensive research, so far no specific 
pathogenic microorganism has been shown to be directly associated with any of these 
models. In addition, it is known that antigens from most resident bacteria do not take 
part in the disease process, there is little evidence that pathogenic antigens come from a 
single organism, or even a restricted group of organisms (Cong et al., 1998). 
Furthermore, it is possible to induce disease in various models of mucosal inflammation 
by the introduction of a single microorganism into an otherwise germ-free host (Tab. 1). 
Although this shows that mucosal inflammation can be caused by a limited set of 
antigens, it does not imply that only the organism introduced causes disease in the 
model used or in any other model.  
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Table 1: Bacteria related models of inflammatory bowel disease 
Animal model 
 
SPF 
 
Germfree Bacteria 
 
CD4+CD45RBhigh 
SCID transfer 
 
 
Colitis 
 
No Colitis 
 
B. vulgaris 
IL-10 KO 
 
Colitis, gastritis No inflammation Not B. vulgaris 
IL-2 KO 
 
 
Colitis,gastritis, 
hepatitis 
Attenuated 
inflammation 
ND 
TCR KO 
 
Colitis No inflammation ND 
            (adapted from Sator, 1995)  
 
Finally not all members of the microflora necessarily represent pathogens in IBD. 
Evidence has recently emerged that a class of microorganisms, collectively described as 
‘probiotics’, prevent rather than induce inflammation (Madson et al., 1999).  
 
2.3 Probiotics 
Probiotics are living microorganisms that have a beneficial effect on health by positively 
affecting the microbial environment. Probiotic candidates are usually lactobacilli or 
bifidobacter, but E.coli and other species have also been used to study probiotic effects. 
Probiotics are usually given as food supplements either alone or in combination with 
certain dietary polysaccharides that might independently affect the enteric flora. 
Probiotic treatment seems to be effective in patients with inflammatory bowel disease, 
and trials in animals with Crohn’s disease have been encouraging (Shanahan, 2002; 
Shanahan 2001; Campieri et al., 1998). A change in the enteric flora might also 
contributes to the therapeutic effect of elemental and polymeric diets in patients with 
Crohn’s disease. 
Possible mechanisms of probiotic action in inflammatory bowel disease include the 
production of antimicrobial factors, competitive interaction with pathogens, and 
signaling with the epithelium (Shanahan, 2000). Epithelial signaling by some non 
pathogenic bacteria might have an anti-inflammatory effect by blocking degradation of 
IκB, which inhibits NF-κB (Neish et al., 2000). Probiotic effects in vivo have been 
shown to include changes in the permeability of the intestine and in function of the 
mucosal immune system. However, use of genetically engineered probiotic organisms 
should extend the scope of probiotic action to include localized delivery of anti-
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inflammatory and other biologically relevant molecules to the inflamed mucosa (Steidler 
et al., 2000; Shanhan, 2000). As an example, food-grade Lactococcus lactis has been 
engineered to secrete IL-10 and was therapeutically effective when given intragastrically 
to mice with IBD (Steidler et al., 2000). According to this beneficial abilities, probiotics 
are predestined to be used as carrier organisms for gut focused drug specific therapy of 
IBD, but the use of the therapeutic potential of probiotics is likely to require more 
detailed understanding of the normal intestinal microflora.  
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3 Homeostasis of the intestinal immune system 
 
The mucosal immune system has the crucial role in maintaining the balance between 
defense against pathogens and accommodation of non-pathogenic resident bacteria as 
well as the many potentially immunogenic dietary proteins (mucosal tolerance). In 
contrast to DCs in the systemic immune system, mucosal DCs seem to preferentially 
induce Treg cells (Harrison & Hafler, 2000; Faria & Weiner, 1999; Viney et al., 1998; 
Weiner, 2001). This properties of the mucosal immune system might be due to the 
mucosal milieu, with its high concentration of anti-inflammatory cytokines, such as 
TGF-β, IL-4 and IL-10. In addition intestinal epithelial cells express MHC class II 
molecules (Mayrhofer & Schon-Hegrad, 1983) and have been shown to process and 
present antigen to primed CD4+ T cells (Meyer & Shlien, 1987; Kaiserlian et al., 1989), 
but they might not be professional antigen-presenting cells in the sense that they do not 
provide appropriate costimulatory signals for the induction of fully competent immune-
effector cells. Therefore, antigen presentation by these cells might also lead to the 
development of Treg cell. 
In the intestinal immune system different types of regulatory T cells with specific 
regulatory functions develop. First to mention the TH3 cells, a population of CD4+ T 
cells that produce transforming growth factor-β (TGF-β) and can be generated by 
repeated restimulation of mesenteric lymph node or splenic lymphocytes from mice that 
have been fed low dose of antigen for oral tolerance induction. Similar cells have been 
identified directly in vivo (Miller et al., 1992). A second population of regulatory T cells 
are the Tr1 cells. This population of CD4+ T cells produce high amounts of IL-10. They 
can be generated in vitro in the presence of antigen, IL-10, IL-15 and/or type I 
interferon. These cells have not been isolated following oral tolerance induction in vivo, 
but have been shown to confer bystander suppression in experimental colitis in mice that 
have been fed with antigen (Groux et al., 1997). The third Treg population is represented 
by intrathymic derived regulatory CD4+CD25+ T cells showing a potent ability to 
prevent auto-reactivity in vivo. Although few reports have described the induction of 
these cells by specific antigen in the periphery, one study has identified ovalbumin-
specific CD4+CD25+ T cells with regulatory activity after feeding tolerogenic doses of 
antigen to mice (Thorstenson & Khoruts, 2001) and Walker et al. (2003) published a 
model in which Treg population dynamics are shaped by the local antigenic environment. 
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Figure 5: Proposed role of the 
intestinal microenvironment 
in polarizing immune 
functions. (a) Food proteins 
and products of commensal 
bacteria are taken up by DCs. In 
the absence of inflammation 
prostaglandin PGE2, TGF-β, 
and IL-10 production result in a 
partial maturation of DCs in the 
Peyer’s patch or lamina popria. 
The antigen is than presented to 
naïve CD4+ T cells in the MLN 
or Peyer’s patch. These cells 
can differentiate into regulatory 
T cells, which produce IL-10 
and/or TH3 cells, which 
produce TGF-β with die 
induction of  local IgA 
production, systemic tolerance 
and local immune homeostasis. 
(b) By the uptake of pathogens, 
local inflammation is induced 
by effects of pathogen products 
mediated through Toll-like 
receptors that are expressed by 
mesenchymal cells, macro-
phages and epithelial cells. As 
result, DCs in the Peyer’s patch 
or lamina propria mature completely after antigen uptake and produce IL-12. After migrating to the MLN, 
these DCs prime gut-homing TH1 cells, which produce INF-γ and cause further inflammation. CCR, CC-
chemokine receptor; LPS, lipopolysaccharide; PAMP, pathogen-associated molecular pattern (adapted 
from Mowat, 2003). 
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CD8+ suppressor T cells represent the first population of regulatory T cells identified. 
They have been thought to be involved in oral tolerance induction (Mowat, 1987), but 
their functions and characteristics have not been clearly defined. T cells expressing a γδ 
TCR represent an additional population of regulatory T cells. Several studies in knock-
out mice indicate that these cells play an important role in some models of oral 
tolerance. Indeed, tolerance can be transferred to untreated mice by injection of γδ T 
cells isolated from orally tolerized mice (Ke et al., 1997). 
A model for the induction of regulatory T cells in the intestinal environment is shown in 
Fig. 5a. Food proteins and products of commensal bacteria are taken up by DCs in the 
absence of inflammation; prostaglandin E2 (PGE2), TGF-β and perhaps IL-10 results in 
the partial maturation of DCs in the Peyer’s patches or lamina propria. The antigen is 
then presented to naïve CD4+ T cells in the MLN or Peyer’s patches. These T cells 
differentiate into regulatory T cells, which produce IL-10 and IFN-γ, and/or TH3 cells, 
which produce TGF-β. The immunological consequences are local IgA production, 
systemic tolerance and local immune homeostasis. In Fig. 5b the situation after 
pathogen contact in the intestine is shown. The local inflammation is induced by the 
effects of pathogen products mediated through toll like receptors that are expressed by 
mesenchymal cells, macrophages and epithelial cells. As a result, DCs in the Peyer’s 
patches or lamina propria mature completely after taking up antigen and produce IL-12. 
After migration to the MLN, these DCs prime gut-homing TH1 cells, which produce 
IFN-γ and cause further inflammation. The result of the interaction between intestinal 
contents, unique anatomical features, and immune and non-immune cells is an 
environment that favors the induction of IgA antibodies and regulatory-T-cell-dependent 
tolerance. This ensures that a homeostatic balance is maintained between the intestinal 
immune system and its antigen load, retaining the ability to recognize both dangerous 
and harmless antigens as foreign, and preserving the integrity of the intestinal mucosa. 
Inappropriate immune response to food and commensal bacteria may result in 
inflammatory response pattern as encountered in IBD. 
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4 Oral tolerance 
 
The ability of the mucosal immune system to distinguish between harmful and harmless 
antigens is essential for mounting protective immune responses and preventing the 
induction of mucosal pathology. One of the mechanisms inhibiting a reactive immune 
response is the oral tolerance induction. Oral tolerance is defined as the induction of a 
state of systemic immune unresponsiveness to orally administrated antigen upon 
subsequent antigen challenge. This mechanism presumably prevents the development of 
an immune reaction or allergy against intestinal intraluminal antigens. However, the 
inductive site of oral tolerance and the type of antigen-presenting cells generating the 
tolerogenic immune response are not yet defined. T cells appear to be the major target of 
tolerance, and the reduction of antibody responses after antigen feeding are due to a 
reduction in T helper activity rather than to direct tolerization of B cells.  
 
 
 
 
 
 
 
 
 
Figure 6: Antigen presentation and tolerance induction. Antigen has to be taken up by APCs. The 
activation state of the APC has a crucial role in determining the outcome of the ensuing APC-T cell 
interaction. The absence of an antigen-specific T cell is tolerance in its purest sense. At the other end 
of the spectrum, a fully activated APC induces T cell activation. Some activated lymphocytes might 
then undergo activation-induced-cell-death (AICD) and deletion by apoptosis. The intermediate zone 
between no activation and full cellular activation is connected to Treg cells. Partial activation can 
generate T cells that are anergic and that have properties of Treg cells, including the ability to render 
APCs ‘tolerogenic’ (adapted from  Herrath & Harrision, 2003). 
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The major mechanisms of tolerance induction are clonal deletion, clonal anergy and the 
induction of suppressor cells (Weiner, 1997; Weiner, 2001). IL-12, a TH1-directing 
cytokine, may be the key regulatory cytokine for these various pathways in the mucosal 
immune response. Factors that suppress IL-12 production by antigen presenting cells 
result in suppressor or regulatory T cells producing TGF-β and possibly IL-4 and IL-10, 
while factors that induce IL-12 production result in T cells producing the pro-
inflammatory cytokine IFN-γ (Chen et al., 1997; Kelsall et al., 1994; Marth et al., 1996). 
The nature and localization of the antigen presenting cells responsible for tolerogenic 
presentation of fed antigens are unclear, but T cell activation and/or deletion can be 
rapidly observed in the Peyer’s patches of antigen fed mice (Chen et al., 1996). Oral 
tolerance induction is also a way to protect the organism against autoimmune reactions 
against self antigens and thus to prevent the development of autoimmune disease. 
Nevertheless, further studies are necessary to characterize the pathways of tolerance 
induction in humans and mice before using this approach as a therapeutic tool against 
hyperresponsiveness of the mucosal immune system. 
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5 Inflammatory bowel disease 
 
Inflammatory bowel disease (IBD) is a chronic relapsing and remitting inflammatory 
condition of the gastrointestinal tract that is manifested in two usually distinct but 
sometimes overlapping clinical entities, ulcerative colitis (UC) and Crohn’s disease 
(CD). IBD leads to long-term and sometimes irreversible impairment of the 
gastrointestinal structure and function (summarized in Fig. 7). 
 
5.1 Etiology and pathophysiology of IBD 
IBD is thought to result from inappropriate and ongoing activation of the mucosal 
immune system driven by the presence of the normal luminal flora. This aberrant 
response is most likely facilitated by genetic prepositions and defects in both the barrier 
function of the intestinal epithelium and the mucosal immune system. 
 
5.1.1 Genetic factors 
It has been shown in a variety of different mouse models that genetic defects can lead to 
the development of spontaneous mucosal inflammation (Tab. 2), demonstrating that 
entirely different genetic abnormalities can lead to similar clinical features of intestinal 
inflammation. An example for the genetic predisposition to IBD is represented by the 
nod2/card15 gene. About 20 % of patients with Crohn’s disease have mutations in this 
gene, which is involved in the regulation of host responses to bacteria (Hampe et al., 
2001). Recently, common structural and functional features between human and mouse 
NOD2 have been identified (Iwanaga et al., 2003). This should allow the development 
of relevant animal models to evaluate the role of NOD2 in chronic inflammatory 
disorders. 
Additionally, the host genetic background determines the susceptibility of intestinal 
inflammation, even when this is due to a major genetic defect. For example, some 
inbred mouse strains with IL-10 deficiency are highly susceptible to colitis, while others 
are resistant (Mahler & Leiter, 2002). These differences in disease susceptibility and 
resistance among mouse strains offer the opportunity to identify murine genes which 
plam 
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Figure 7: Characteristics of inflammatory bowel disease. 
 
What is inflammatory bowel disease? 
 
General definition 
Inflammatory bowel disease (IBD) is a chronic relapsing idiopathic inflammation of the gastrointestinal tract. The two 
main forms of IBD — Crohn's disease and ulcerative colitis — have many similarities, but there are also several clinical 
and pathological differences. In a small minority of cases that involve only the colon, they are indistinguishable and 
categorized as 'indeterminate colitis'. 
 
Epidemiology 
Both Crohn's disease and ulcerative colitis have a prevalence range of 10–200 cases per 100,000 individuals in North 
America and Europe. Disease incidence is the highest in developed, urbanized countries. The incidence of Crohn's 
disease has increased during the past four decades, whereas no clear trend is identifiable for ulcerative colitis. 
 
Areas of involvement 
Crohn's disease. Any part of the gastrointestinal tract can be affected, but most commonly, the terminal ileum, cecum, 
peri-anal area and colon. It is characterized by the presence of segments of normal bowel between affected regions, 
known as 'skip' lesions. The intersection of linear ulcers with islands of normal or oedematous mucosa might produce a 
'cobblestone' appearance. 
Ulcerative colitis. The inflammatory process invariably involves the rectum and extends proximally in a continuous 
fashion, yet remains restricted to the colon. Sometimes, it is limited to the rectum as 'ulcerative proctitis'. 
 
Histology 
Crohn's disease. A transmural (affecting all layers of the bowel wall), dense infiltration of lymphocytes and 
macrophages; presence of granulomas in up to 60% of patients; fissuring ulceration and submucosal fibrosis (see left-
hand figure). 
Ulcerative colitis. Inflammation affects superficial (mucosal) layers with infiltration of lymphocytes and granulocytes and 
loss of goblet cells. Presence of ulcerations and crypt abscesses (see right-hand figure).  
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(Left). Photomicrograph of a histological specimen taken from a patient with Crohn's disease. Inflammation can be 
seen to involve the full thickness of the wall from the mucosa to the serosa. Granulomas are seen towards the 
serosal surface. 
Right). Ulcerative colitis is shown microscopically here at low-power magnification to show mucosal inflammation 
and erosion. High-power magnification might show the presence of acute inflammatory cells in crypts, known as 
'crypt abscesses'. Images courtesy of Edward C. Klatt at Florida State University College of Medicine. linical features and complications 
rohn's disease. Diarrhea, pain, narrowing of the gut lumen leading to strictures and bowel obstruction, abscess 
ormation, and fistulization to skin and internal organs. 
lcerative colitis. Severe diarrhea, blood loss and progressive loss of peristaltic function leading to rigid colonic tube. In 
evere cases, this can lead to 'toxic megacolon' and perforation. 
xtra-intestinal inflammatory manifestations in joints, eyes, skin, mouth and liver can occur in both forms of IBD. 
ncreased risk for colon carcinoma in longstanding IBD — in particular, ulcerative colitis. 
 
urrent treatments  
rohn's disease. 5-ASA compounds, corticosteroids, azathioprine/6-MP, methotrexate, antibodies specific for tumour-
ecrosis factor (TNF) and surgical removal of obstructing segments. 
lcerative colitis. 5-ASA compounds, corticosteroids, azathioprine/6-MP, intravenous cyclosporin and colectomy. 
                        Bouma & Strober, 2003 
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play a important role in disease onset and progression, and might therefore contribute to 
the identification of genes necessary for the occurrence of disease in humans. 
 
5.1.2 Dysregulation of the mucosal immune system 
Besides the genetic predisposition the interaction between the intestinal microflora and 
the mucosal immune system plays a key role in the development of IBD (paragraph 
2.2). The immunological nature of the disease arises from the observation that IBD is 
characterized by massive cellular infiltrates and is associated with abnormalities of the 
immune system that include inappropriate production of antibodies and T cell 
dysfunction. This concept has been clarified by studies in human patients with CD. 
Lamina propria cells showed an overproduction of cytokines indicative of a typical 
helper TH1 response, namely increased production of IL-12 by LP macrophages and 
increased production of INF-γ by LP T cells (Fiocchi, 1998; Fuss et al., 1996; 
Monteleone et al., 1997). In addition, LPL from patient with UC developed a cytokine 
profile resembling a TH2 response. More precisely, LPL from UC patients do not 
produce high levels of the major TH2 cytokine IL-4, but they produce increased amounts 
of another TH2 cytokine IL-5. These studies provide circumstantial evidence that the 
two major forms of IBD in humans are a consequence of dysregulated or excessive TH1 
(CD) or TH2 (UC) responses. There is considerable evidence that IBD patients have 
inappropriate T cell responses to their own intestinal flora, either because of dysfunction 
in the primary or secondary mechanisms that normally drive and regulate such responses 
or due to some dysfunction in the intestinal epithelial cell barrier that leads to 
inappropriate penetration of microbial agents (Duchmann et al., 1995; Soderholm et al., 
1999; Probert et al., 1996). In effect, patients with IBD have a failure in the maintenance 
of oral tolerance including down-regulation of responses to harmless luminal antigens 
like commensals or food, while allowing effector cell responses to mucosal pathogens. 
 
5.2 Animal models of mucosal inflammation 
In the recent years the status of IBDs as canonical autoimmune diseases has risen 
steadily with recognition that these diseases are abnormalities in mucosal responses to 
normally harmless antigens derived from the mucosal microflora and therefore 
responses to antigens that, by their proximity and persistence, are equivalent to self-
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antigens (Strober et al., 2002). This new paradigm is consistent with the fact that 
multiple murine models (Tab. 2) of mucosal inflammation exist which affect the 
immunological balance and can lead to loss of tolerance to mucosal antigens and thus 
inflammation centered in the gastrointestinal tract. All models have their individual 
capacities to provide insights into IBD pathogenesis. It emerges that murine models of 
mucosal inflammation will allow to define and understand the immunology of IBD in all 
its complexity and to find unexpected ways to treat these diseases. 
Most models for IBD are based on dysregulated effector functions or changes in the 
regulatory processes. The great majority of existing models are TH1 based models. One 
explanation relates to the fact, that in most if not all models the inflammation is driven 
by antigens of the normal mucosal microflora like LPS, CpG-motive or superantigens 
(Strober et al., 2002). The mitogen-lymphocyte interaction predominantly induces an 
IL-12 dependent TH1 immune response. Moreover, the regulatory effect of the cytokines 
TGF-β and IL-10 is mainly based on TH1 responses. Also the nature of the antigen is an 
important factor for the developing immune response. It was shown that two classical 
skin sensitizing agents induced different forms of inflammation in mice. Trinitrobenzene 
sulfonic acid induces a TH1 response in SJL/J mice and oxazalone promotes a non 
classical TH2 response in these mice (Boirivant et al., 1998). 
 
5.2.1 Chemically induced models 
This group of models requires administration of a chemical agent for the induction of 
colitis. Examples include trinitrobenzene sulfonic acid (TBNS) (Morris et al., 1989), 
dextran sodium sulfate (DSS) (Okayasi et al., 1990), and oxazolone (Boirivant et al., 
1998). Chemically induced models are useful for studying biochemical pathways of 
inflammation or for performing antigen-specific studies, such as in the case of hapten-
induced gut inflammation (TBNS). In addition, these models are particularly valuable in 
the dissection of specific aspects or events on the overall background of intestinal 
inflammation. For example, DSS-induced colitis is characterized by epithelial disruption 
resulting in luminal bacterial translocation and subsequent infiltration of neutrophils and 
other acute phase immune cells. However, although these events might be important in 
initiating gut inflammation, DSS colitis can be induced in the absence of lymphocytes 
(Dielman et al., 1998), and does not represent the chronic phases of disease. Therefore, 
DSS colitis can be considered as an appropriate animal model to investigate epithelial 
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response to injury, neutrophil infiltration or other aspects of the acute phase of colitis 
pathogenesis, but this not adequately addresses those events occurring during the 
chronic phase of gut inflammation. Nevertheless, important informations have been 
derived using these experimental systems, in particular studies regarding the pathogenic 
role of specific cytokines in experimental colitis (Neurath et al., 1995). 
 
 
Table 2: Commonly used mouse models of intestinal inflammation and IBD 
Animal model 
 
Disease type  
 
Reference 
 
Chemically induced 
  
 
TNBS 
 
Colitis, acute, chronic,  
transmural, TH1 
 
Morris et al., 1989 
DSS  Colitis, superficial, Th1  
(acute), TH1/TH2 (chronic) 
Okayasi et al., 1990 
Oxazolone Colitis, TH2 Boirivant et al., 1998 
   
Immunological 
 
  
CD4+CD45RBhigh SCID 
transfer 
 
Colitis, chronic transmural,  
TH1 
Morrissey et al., 1993 
Tgε bone marrow  
chimera 
Colitis, TH1 Hollander et al., 1995 
   
Genetic 
 
  
IL-10 KO Colitis, acute, chronic,  
transmural, TH1 (early) / TH2  
(late) 
Kuhn et al., 1993 
TNF∆ARE Ileocolitis, chronic, TH1, 
transmural, granulomatous 
Kontoyiannis et al., 1999 
   
Spontanous 
 
  
C3H-HeJBir Cecitis, superficial, acute  
resolving, TH1 
Sundberg et al., 1994 
SAMP1/Yit Ileitis, chronic, transmural, 
granulomatous, TH1 
Matsumoto et al., 1998 
SAMP1/YitFc Perianal disease, early onset  
of disease 
Rivera-Nieves et al., 2003 
 
 
Abbreviations: DSS, dextran sodium sulphate; SCID, severe combined immunodeficient, TNBS, 
trinitrobenzene sulfonic acid (adapted from Pizzaro et al., 2003). 
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5.2.2 Immunological models 
Immunological induced models for IBD are mainly based on adoptive transfer of T cells 
or bone marrow precursors, which are introduced into immunodeficient recipient mice. 
Classical examples are the CD4+CD45RBhigh (Morrissey et al., 1993), the bone marrow 
chimera (Hollander et al., 1995) and the CD4+CD25- (Mottet et al., 2003) transfer 
model. Furthermore, the transfer of hsp60-reactive CD8+ T cells is also sufficient to 
induce intestinal inflammation, primarily in the small intestine (Steinhoff et al., 1999). 
Studies in these models have elucidated the role of pathogenic and regulatory T cells in 
controlling mucosal immunity and intestinal inflammation and offer strong evidence 
that TH1 polarization plays a key role in CD pathogenesis (Powrie, 1995). However, the 
profound immune abnormalities in the recipient mice with totally absence of T and B 
cells probably make these models unsuitable for investigating the innate factor causing 
human CD. 
5.2.3 Genetic models 
Transgenic and knock-out methodologies have revolutionized the field of animal models 
for to IBD. With the exception of a few transgenic models (e.g. E-cadherin transgenic 
mice), the majority of these genetic mouse models are gene knock-outs. Examples 
include IL-2 (Sadlack et al., 1993), TCR αβ (Mombaerts et al., 1993), IL-10  (Kuhn et 
al., 1993), and Gi1-a  (Rudolph et al., 1995) knock-out models. Genetic models greatly 
contribute to our understanding of the role of key immune-related molecules in the 
pathogenesis of chronic intestinal inflammation. Collectively, these models have clearly 
established the requirement for strict regulation of the mucosal immune response and 
have allowed the identification of key components involved in gut immune regulation. 
However, it is unlikely that the imposed genetic mutations represent the underlying 
defect in human IBD, limiting the utility of these models for understanding causative 
factors in both ulcerative colitis and Crohn’s disease. 
5.2.4 Spontaneous models 
Spontaneous models represent one of the most attractive tools for studying intestinal 
inflammation, because similar to human disease inflammation occurs without any 
apparent exogenous manipulation. For example, the C3H/HeJBir murine model of 
colitis is characterized by spontaneous and chronic focal inflammation localized to the 
right colon and cecal region. Colitis occurs in young mice and tends to resolve with age 
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without recurrence (Sundberg et al., 1994). In these spontaneous models it is possible to 
study the role of immunobacterial interactions for the induction and chronicity of 
intestinal inflammation. 
 
5.3 Balance between inflammation and regulation 
As a rule, chronic colitis only occurs when the appropriate microbial agent stimulates 
mucosal immune responses in genetically susceptible hosts. In genetically resistant 
hosts, intestinal homeostasis is maintained by exclusion of luminal microbial 
constituents by an intact mucosal barrier and a net suppressive tone of the mucosal 
immune system, leading to immunologic tolerance to autologous bacteria (Fig. 8). 
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Figure 8: Balance between luminal pro-inflammatory factors and mucosal protective mechanisms. 
The genetically determined immune response to bacterial products and epithelial barrier functions can 
influence host susceptibility to chronic inflammation, while environmental factors can influence initial 
onset and spontaneous reactivation of inflammation (adapted from Sartor, 1997). This delicate balance can be perturbed by genetic defects of immune regulation and 
barrier functions as well as by environmental triggers which can initiate a reactive 
disease. A variety of genetic alterations can adversely affect immune regulation and 
barrier functions, leading to phenotypically similar chronic intestinal inflammation. The 
luminal microbial environment is incredible complex, with over 300 - 500 individual 
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bacteria strains. This complexity may be even further augment if different genetic 
subsets of patients respond to different dominant bacterial stimuli, as suggested by 
animal models. However, recent investigations in animal models provide hope that 
selective elimination of dominant bacterial antigenic stimuli by specific antibiotics or 
even competition with probiotic strains can complement new selective immunotherapies 
against chronic intestinal inflammation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CHAPTER II
Induction of chronic mucosal inflammation 
in mice by enterocyte-specific CD4+ T cells
CHAPTER II  32 
Induction of chronic mucosal inflammation in mice by 
enterocyte-specific CD4+ T cells 
 
1 Background 
Several studies have suggested that chronic inflammatory bowel disease might be a 
consequence of antigen specific recognition of appropriate T cells which expand and 
induce immunopathology. Since the intestinal immune system has to discriminate 
between harmless antigens derived from nutrients or bacterial flora on the one hand and 
harmful antigens derived from pathogens on the other hand, induction and maintenance 
of mucosal tolerance is of indispensable importance to avoid inappropriate immune 
responses in the gut (Nagler-Anderson, 2001). Central tolerance induction takes place in 
the thymus, where clonal deletion of potentially auto-reactive T cells occurs (Kisielow 
et al., 1988; von Boehmer et al., 2003). However, in few cases auto-reactive T cells 
escape thymic deletion, but these T cells are usually rendered anergic due to the absence 
of costimulatory signals on their target tissue in the periphery (Melamed & Frieman, 
1993). Because of the huge variety of antigens and the large number of lymphoid cells 
in the intestine, minor dysfunctions of mucosal immune homeostasis may result in 
intestinal immune responses resulting in inflammation and chronic disease (Monteleone 
et al., 2002). Therefore, additional tolerance mechanisms must exist to tightly control 
inappropriate immune responses. It has been shown that maintenance of tolerance in the 
gut can be mediated by natural occurring CD4+CD25+ or CD4+CD45RBlow regulatory T 
cells which suppress uncontrolled immune responses most likely towards luminal 
antigens (Sakaguchi, 2003). This is achieved by secretion of regulatory cytokines like 
interleukin (IL)-10 and transforming growth factor (TGF)-β (Powrie et al., 1994; De 
Winter et al., 2002). Regulatory T cells suppress intestinal pathology mediated by T 
cells, but until now it remains unclear how they elicit their effector function in vivo 
(Maloy & Powrie, 2001). 
 
 
 
 
CHAPTER II  33 
2 Aims of the study 
To analyze the immunological and molecular mechanisms of autoantigen-specific CD4+ 
T cell response in chronic mucosal inflammation a transgenic mouse expressing 
hemagglutinin A/PR8/34 (HA) under the control of the gut-specific villin promotor in 
enterocytes of the intestinal epithelium was generated (Templin et al., submitted). To 
establish an autoimmune environment these VILLIN-HA mice were crossed with TCR-
HA mice expressing a transgenic T cell receptor specific for the MHC class II restricted 
peptide HA110-120 (Kirberg et al., 1994). Concomitant expression of HA and a MHC 
class II-restricted T cell receptor specific for HA resulted in an autoimmune mediated 
chronic intestinal inflammation. The mild form of mucosal inflammation suggested the 
induction of peripheral tolerance mechanisms. To study these mechanisms in more 
detail, extensive immunological characterization of self-reactive T cells should be 
performed including: 
 
• Isolation of peripheral self-reactive enterocyte specific T cells from VILLIN-HA x 
TCR-HA double transgenic mice and TCR-HA control mice to characterize the 
proliferative capacity and their activation status. 
 
• Morphological evaluation of the intestine from VILLIIN-HA x TCR-HA double 
transgenic to define the degree of intestinal disease. 
 
• Isolation of auto-reactive intestinal T cell from VILLIN-HA x TCR-HA double 
transgenic mice to characterize their proliferative capacity. 
 
• Stimulation of the auto-reactive intestinal T cells and determination of the cytokine 
secretion profile in autoimmune mediated chronic intestinal inflammation. 
 
• Gene expression profiling of self-reactive intestinal T cell from double transgenic 
VILLIN-HA x TCR-HA mice and TCR-HA control mice. 
 
• Studies on the impact of naturally occurring Treg cells on the outcome of disease in an 
adoptive transfer system based on VILLIN-HA single transgenic mice. 
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3 Results 
3.1 Enterocyte-specific CD4+ T cells are present in the periphery of 
VILLIN-HA x TCR-HA mice and proliferate upon antigen 
stimulation 
The prerequisite for the development of autoimmunity is inefficient thymic deletion of 
the T cell recognizing self-antigens resulting in the presence of auto-reactive T cells in 
the periphery. Therefore, a key question to answer was whether HA-specific (6.5+) 
CD4+ T cells mature in the thymus of VILLIN-HA x TCR-HA double transgenic mice 
and thus can be found in peripheral lymphoid organs. To this end, T cells from spleen 
and MLN of VILLIN-HA x TCR-HA and TCR-HA control mice were isolated and 
analyzed by flow cytometry for the expression of the transgenic T cell receptor (Fig. 1). 
 
 
Figure 1: HA-specific CD4+ T cells 
in the periphery of VILLIN-HA x 
TCR-HA mice. VILLIN-HA x TCR-
HA and TCR-HA control mice were 
sacrificed, spleen and MLN cells were 
isolated and stained for 6.5 and CD4 
expression to measure the percentage 
of transgenic T cells in the different 
compartments. 
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Indeed, HA-specific 6.5+CD4+ transgenic T cells could be detected in the peripheral 
lymphatic organs. In the spleen of VILLIN-HA x TCR-HA 2.5 % of the CD4+ T cells 
carry the transgenic T cell receptor compared to 6.5 % in the MLN of the double 
transgenic mice. Transgenic cell numbers were decreased in comparison to TCR-HA 
control mice, suggesting that thymic HA expression in the VILLIN-HA x TCR-HA 
transgenic mice leads to thymic deletion of a proportion of 6.5+CD4+ T cells in double 
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transgenic mice. It has been shown previously that expression of HA under control of 
the Ig-κ promoter by hematopoetic cells resulting in permanent antigen expression both 
in thymus and in the periphery leads to tolerance rather than inflammation (Buer et al., 
1998). Therefore, it was reasonable to analyze whether mature 6.5+CD4+ T cells found 
in the peripheral lymphoid organs of VILLIN-HA x TCR-HA double transgenic mice 
are functional with respect to their proliferative capacity upon antigen encounter. To this 
end, T cells from spleen and MLN of VILLIN-HA x TCR-HA and TCR-HA control 
mice were isolated and stimulated in vitro with the specific HA peptide. Flow cytometry 
analysis and normalization of cell numbers ensured that the same percentage of 
6.5+CD4+ T cells from double and single transgenic mice were used for the experiments. 
Apparently, enterocyte-specific expression of HA did not lead to tolerance induction in 
peripheral compartments, as demonstrated in Fig. 2. No differences in their capacity to 
proliferate upon stimulation with their cognate peptide could be observed between T 
cells isolated from double-transgenic VILLIN-HA x TCR-HA and TCR-HA mice that 
served as controls (Fig. 2). 
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Figure 2:. Proliferative capacity of HA-
specific CD4+ T cells from spleen and MLN 
of VILLIN-HA x TCR-HA mice and TCR-
HA control. Splenic and lymph node cells 
from VILLIN-HA x TCR-HA and TCR-HA 
control mice were isolated and identical 
numbers of antigen specific 6.5+CD4+ T cells 
from spleen (A) and MLN (B) were used for in 
vitro proliferation assays in presence or absence 
of 10µg/ml HA-peptide. Proliferation was 
measured by 3[H]-thymidine incorporation. 
Black bars represent proliferation of T cells 
from TCR-HA control mice and grey bars 
proliferation of VILLIN-HA x TCR-HA 
derived cells. 
B 
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3.2 HA-specific CD4+ T lymphocytes from VILLIN-HA x TCR-HA 
mice have an activated phenotype  
To characterize peripheral 6.5+CD4+ T cells from VILLIN-HA x TCR-HA mice in more 
detail, these cells were analyzed for the expression of the activation and memory 
markers CD69, CD25, CD45RB and CD62L by flow cytometry (Fig. 3). Comparing the 
expression patterns of VILLIN-HA x TCR-HA and TCR-HA mice revealed that in the 
spleen and the MLN of VILLIN-HA x TCR-HA mice the expression of CD45RB was 
drastically decreased. In the spleen of VILLIN-HA x TCR-HA there is an increased 
amount of CD69-positive T cells compared to TCR-HA mice, which was even more 
prominent in the MLN of VILLIN-HA x TCR-HA mice. Compared to TCR-HA mice 
the percentage of CD25+ T cells was increased in spleen and MLN of double transgenic 
mice.  
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 Figure 3: Activation pattern of HA-specific CD4+ T cells from double transgenic VILLIN-HA x 
TCR-HA mice compared to TCR-HA mice. 6.5+CD4+ T cells were isolated from spleen and MLN of 
VILLIN-HA x TCR-HA and TCR-HA mice, respectively. Lymphocytes were stained with antibodies 6.5 
and CD4 as well as with CD25, CD45RB, CD62L, CD69 antibodies. Cells were gated for 6.5 and CD4 
expression on splenocytes (A) and MLN (B) and analyzed regarding the expression of the different 
activation/memory markers by FACS.  
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Additionally the expression of the surface marker CD62L (L-selectin) was determined 
which is highly expressed on naïve T lymphocytes, but is down-regulated upon 
activation of T cells. Again, the percentage of 6.5+CD4+ T cells isolated from spleen and 
MLN that not expressing CD62L was significantly increased in double transgenic mice 
compared to control TCR-HA mice. Comprising, peripheral HA-specific CD4+ T cells 
from VILLIN-HA x TCR-HA transgenic mice showed an activated phenotype. 
 
3.3 Morphological evaluation of the intestine 
As mature 6.5+CD4+ T cells of VILLIN-HA x TCR-HA transgenic mice can be found in 
the periphery of these mice and these autoantigen-specific T cells are able to proliferate 
upon stimulation with their corresponding antigen and have an activated phenotype, the 
ability of the 6.5+CD4+ T cells to infiltrate the intestine, i.e. the compartment where the 
antigen is located, was investigated. The small intestine of VILLIN-HA x TCR-HA and 
TCR-HA control mice was isolated, fixed in formalin, embedded in paraffin and 
sectioned. Sections were H&E stained and immunohistochemistry was performed to 
identify T cells in the intestine. The evaluation revealed increased numbers of IEL and 
LPL with moderate lymph edema in the intestine. However, tissue damage to the 
epithelial cell layer could not be observed, suggesting a mild form of mucosal 
inflammation (Fig 4). 
 
 
VILLIN-HA xTCR-HA TCR-HA
 
 
Figure 4: Mild enterocolitis in 
VILLIN-HA x TCR-HA double 
transgenic mice characterized by 
infiltration of lymphocytes into the 
lamina propria and intestinal 
epithelium. Intestinal villi are distended 
(arrow) by increased numbers of 
lymphocytes (left panel) when compared 
to intestinal villi of TCR-HA transgenic 
mice (right panel). Similarly, the number 
of intraepithelial lymphocytes (IEL) is 
increased  (insets).  Insets  show  α-CD3 
immunohistochemistry on paraffin-embedded tissues. ABC method with diaminobenzidine as substrate 
(brown color) and hematoxylin counterstain (blue nuclei). Ileum, H&E stain, scale bar: 80 µm.   
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3.4 Functional and molecular characterization of auto-reactive 
intestinal CD4+ T cells 
It is well established, that mucosal lymphocytes are relatively unresponsive to T cell 
receptor dependent stimulation compared to peripheral blood lymphocytes. To evaluate 
the responsiveness of auto-reactive 6.5+CD4+ T cells isolated from the small intestine to 
antigenic stimulation, IEL and LPL from VILLIN-HA x TCR-HA as well as TCR-HA 
control mice were isolated and stimulated in vitro with the corresponding peptide. 
Proliferation was measured by 3[H]-thymidine incorporation and culture supernatants 
were analyzed for several cytokines by cytokine bead array.  
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Figure 5: Reduced proliferative capacity of 
HA-specific IEL from VILLIN-HA x TCR-HA 
mice. LPL (A) and IEL (B) were isolated from 
VILLIN-HA x TCR-HA and TCR-HA control 
mice and stimulated in vitro with the 
corresponding HA-peptide. Thymidine 
incorporation was referred to cpm per thousand 
6.5+CD4+ T cells. Proliferation of responder cells
from TCR-HA mice is depicted in black bars and 
in grey bars for VILLIN-HA x TCR-HA derived 
cells. 
B 
 
 
LPL from VILLIN-HA x TCR-HA mice as well as LPL from TCR-HA mice proliferate 
in a dose dependent manner. In contrast, the proliferative capacity of IEL from VILLIN-
HA x TCR-HA mice to antigenic stimulation was abrogated with a high background 
proliferation in comparison to IEL from TCR-HA single transgenic mice (Fig. 5).  
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Fig. 6 and Fig. 7 show the cytokine secretion profiles of LPL and IEL from VILLIN-HA 
x TCR-HA and TCR-HA control mice. Antigen-stimulated 6.5+CD4+ LPL from 
diseased mice secrete significantly lower amounts of IFN-γ and IL-2 upon in vitro 
stimulation, both of which are cytokines normally involved in the induction of gut 
inflammation (Fiocchi, 1998). Additionally, IEL from VILLIN-HA x TCR-HA mice 
secreted lower levels of IFN-γ compared to control TCR-HA mice. In contrast, in LPL 
and IEL from double transgenic mice the basal level secretion of TNF-α, MCP-1 and 
IL-6, which are also discussed as important mediators in the context of IBD, was 
considerably increased. 
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 Figure 6: Cytokine profile of HA-specific LPL from the inflamed intestine. LPL from TCR-HA 
(black bars) and VILLIN-HA x TCR-HA (grey bars) mice were stimulated in vitro with the HA110-
120 peptide. Culture supernatants were analyzed for several cytokines using the cytokine bead array 
from BD. Cytokine quantities are depicted as pg/ml per thousand 6.5+CD4+ intestinal T cells.  
CHAPTER II  40 
0 3 10
0
5
10
15
20
25
0 3 10
0
10
20
30
40
50
60
70
0 3 10
0
10
20
30
40
50
0 3 10
0
20
40
60
80
100
120
140
160
180
200
0
1
0 10
180
120
60
TNF- α MCP-1
IFN-γ
0
0
10
20
30
IL-6
Peptide (µg/ml)
40
0
40
80
120
0 3 10
3103
0
10
20
C
yt
ok
in
e
pg
/m
l/
10
6.
5
3
(
)
 
 
 
 
 
 
 
T
t
m
i
o
I
6
 
 
 
 
 
 
 
 
 Figure 7: Cytokine profile of HA-specific IEL from the inflamed intestine. IEL from TCR-HA (black 
bars) and VILLIN-HA x TCR-HA (grey bars) mice were stimulated in vitro with the HA110-120 peptide. 
Culture supernatants were analyzed for several cytokines using the cytokine bead array from BD. Cytokine 
quantities are depicted as pg/ml per thousand 6.5+CD4+ intestinal T cells. ogether, in contrast to LPL, IEL from VILLIN-HA x TCR-HA mice are unresponsive 
o antigenic stimulation and moreover, cytokine pattern of LPL and IEL from diseased 
ice clearly differs from that of TCR-HA control mice. These cytokine data clearly 
ndicate that there is an unbalance in the regulatory environment of the intestine. On the 
ne hand there is a down-regulation of pro-inflammatory cytokines such as IFN-γ and 
L-2, on the other hand LPL and IEL secrete increased levels of TNF-α, MCP-1 and IL-
 even without further antigenic stimulation in vitro. 
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3.5 Global gene expression profiling of self-reactive mucosal CD4+ T 
cells 
As enterocyte-specific antigen expression obviously has a strong impact on the function 
of auto-reactive CD4+ T cells these T cells were extensively characterized by global 
gene expression profiling. CD4+6.5+ T cells from the epithelium and the lamina propria 
of the small intestine of four individual VILLIN-HA x TCR-HA and four TCR-HA mice 
were isolated by cell sorting. RNA was prepared and subjected to differential gene 
expression analysis using Affymetrix MG-U74Av2 oligonucleotide arrays. The 
advantage of this technology is that every gene analyzed is represented by sixteen 
independent probe pairs which together establish the basis for statistical evaluations of 
the respective signals. Therefore, only those genes that are reproducibly regulated are 
included in the analysis. For each gene fulfilling these criteria, the average fold change 
in expression for 6.5+CD4+ IEL and LPL from VILLIN-HA x TCR-HA and TCR-HA 
mice was calculated and the ratio was depicted on a base-2 logarithmic scale. To get an 
impression of the basal expression level of analyzed genes in IEL and LPL under 
normal conditions, an alignment of LPL versus IEL derived 6.5+CD4+ T cells from 
TCR-HA mice was also included. This approach led to a comprehensive overview about 
the functional gene classes involved in autoimmune-mediated intestinal inflammation, 
including surface antigens, regulators of transcription and translation, secreted or 
signaling molecules and genes involved in cell cycle, apoptosis and survival. Six 
clusters of co-regulated genes (Fig. 8 A-F) were found to be of special interest as they 
combine genes either specifically up-regulated (A) or down-regulated (B) in both LPL 
and IEL, exclusively up-regulated (C) or down-regulated (D) in LPL, as well as up-
regulated (E) or down-regulated (F) only in IEL due to intestinal inflammation in 
VILLIN-HA x TCR-HA mice. Noticeable, although the basal level expression of the 
majority of genes analyzed is similar in LPL and IEL (third column, LPL vs IEL), most 
of the differentially expressed genes are regulated exclusively in one of these 
subpopulations of auto-reactive mucosal CD4+ T cells upon intestinal inflammation.  
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 Figure 8: Global gene expression profiling of HA-specific CD4+ T cells. Cluster analysis of genes
differentially expressed in 6.5+CD4+ T cells isolated from lamina propria and epithelium of diseased
VILLIN-HA x TCR-HA as well as healthy TCR-HA mice. Red indicates induction of gene expression,
green indicates repression. As brighter the color as stronger the factor of gene regulation (+3: bright
red; -3: bright green). Black indicates no changes. Inclusion into this heat map required at least a 1.5-
fold difference in inducible gene expression. LPL (infl.), represents genes differentially expressed in
6.5+CD4+ T cells from the inflamed lamina propria of VILLIN-HA x TCR-HA mice compared to the
LPL of healthy TCR-HA donors. IEL (infl.), represents gene differentially expressed in 6.5+CD4+ T
cells from the epithelium of VILLIN-HA x TCR-HA mice compared to TCR-HA. LPL versus IEL
characterizes basal level expression of genes by LPL compared with the IEL of healthy TCR-HA mice.
Cluster A: Genes up-regulated in the LPL and IEL of VILLIN-HA x TCR-HA mice upon gut
inflammation. Cluster B: Genes down-regulated in LPL and IEL during inflammation. Cluster C: 
Genes exclusively expressed by LPL at a higher level than by LPL under healthy conditions. Cluster
D: Genes, which are down-regulated in self-reactive LPL CD4+ T cells in the inflamed gut. Cluster E:
Genes exclusively up-regulated by IEL from inflamed tissue. Cluster F: Genes down-regulated by IEL
from VILLIN-HA x TCR-HA mice. 
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Among the genes analyzed various integrins significantly up-regulated in LPL and/or 
IEL from the inflamed tissue were found. αEβ7  is highly expressed on both LPL and 
IEL, whereas Itgb7 and Itga4 and ItgaV are up-regulated only in LPL from the inflamed 
intestine (Fig.8 A and C). Normally, integrins are involved in lymphocyte homing to the 
intestinal mucosa and it has been demonstrated that their expression is often enhanced 
upon intestinal inflammation. Consequently, anti-adhesion molecule treatment in some 
cases results in attenuated progression of colitis (Elewaut et al., 1998; Sun et al., 2001; 
Hornquist et al., 1997; Ghosh et al., 2003; Van Assche et al., 2002; Podolsky et al., 
1993). Several members of the TNF receptor superfamily (Tnfrsf) were found to be 
differentially expressed in LPL and IEL from double transgenic mice. Elevated numbers 
of peripheral T cells in inflammatory bowel disease display Tnfrsf7 and Tnfrsf9 
(Raedler et al., 1985; Croft, 2003). In line with these results, Tnfrsf7 and Tnfsrf9 were 
up-regulated by self-reactive LPL and IEL from VILLIN-HA x TCR-HA transgenic 
mice (Fig. 8 A). Tnfrsf4 (OX40) shows an ambiguous phenotype of expression. On the 
one hand Tnfrsf4 is expressed on activated CD4+ T cells and constitutive 
Tnfrsf4/Tnfrsf4L interaction induces autoimmune-like diseases (Stüber et al., 2000; 
Murata et al., 2002), on the other hand it is highly expressed on regulatory T cells 
(McHugh et al., 2002; Walkers et al., 2003). In agree with these observations, Tnfrsf4 
expression was also up-regulated in LPL and IEL from diseased VILLIN-HA x TCR-
HA mice (Figure 8 A). Tnfrsf18 (GITR) has been shown to play a key role in 
immunological self-tolerance maintained by CD4+CD25+ regulatory T cells and was 
described as a suitable molecular target for preventing or treating autoimmune disease 
(Shimizu et al., 2002). This molecule was also up-regulated in LPL isolated from 
diseased tissue of VILLIN-HA x TCR-HA transgenic mice (Fig. 8 C). Besides integrins 
and Tnfrsf members, another important group of molecules expressed by LPL and IEL 
and known to be involved in the induction and/or regulation of gut inflammation are 
cytokines. IL-10 expression was highly up-regulated in LPL and IEL of VILLIN-HA x 
TCR-HA transgenic mice compared to control mice (Fig. 8 A). Treg cells are known to 
express high levels of IL-10 and are able to suppress T cell proliferation. It was shown 
that the transfer of IL-10 transduced T cell in SCID mice, results in prevention of colitis 
and trials with human IL-10 secreting CD4+ T cells delivered a novel approach to local 
delivery of immunomodulatory signals to the intestine in IBD (Van Montfrans et al., 
2002). In LPL from diseased tissue also IL-5 was significantly up-regulated (Fig. 8 C). 
It was shown by Fuss et al. (1996) that LPL manifest increased secretion of the TH2 
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cytokine IL-5 in ulcerative colitis. Furthermore, other studies figured out that 
lymphotoxin β (LT-β) is expressed in chronic inflammatory conditions and IL-17 
expression in the mucosa and the serum is increased in IBD patients (Agyekum et al., 
2003; Nielsen et al., 2003; Fujino et al., 2003). In contrast, in LPL from inflamed gut 
tissue in the VILLIN-HA x TCR-HA model the expression of LT-β and IL-17 were 
down-regulated, resembling the regulatory capacity of the intestine to maintain 
immunological balance (Fig. 8 D). In addition to cytokines, the expression of many 
cytokine receptors was found to be regulated. Self-reactive LPL and IEL from inflamed 
intestine expressed lower levels of IL-7 receptor a (IL7ra) than the control lymphocytes 
(Fig. 8 B). A reduced expression of IL-7ra is discussed in the context of regulatory T 
cells (Gavin et al., 2002; Walkers et al., 2003). Another important cytokine receptor 
found to be differentially expressed is the IL-6 receptor a (IL-6ra). This receptor is 
highly expressed on lymphocytes in IBD. Anti-IL-6 receptor monoclonal antibody 
treatment has been shown to inhibit leukocyte recruitment and promote T cell apoptosis 
in a murine model of Crohn’ disease (Ito et al., 2002). However, in our mouse model IL-
6ra expression was decreased in IEL of VILLIN-HA x TCR-HA double transgenic mice 
(Fig. 8 F). A variety of the chemokine receptors and chemokine ligands was regulated in 
double transgenic mice. RNA levels of the chemokine receptors CCR2 and CCR6 were 
up-regulated in 6.5+CD4+ mucosal lymphocytes from double transgenic mice (Figure 8 
E and C), both of which have been shown to participate in the development of a mucosal 
immune response (Cook et al., 2000; Varona et al., 2001). CCR5 expression was down-
regulated in LPL and CCR7 in IEL from inflamed tissue (Fig. 8 D and F). Whereas the 
expression of CCR5 plays an important role in lymphocyte localization within the gut 
(Agace et al., 2000), CCR7 expression could be detected on memory T cells, whereas 
activated T cells down-regulate CCR7 expression (Campbell et al., 2001). The 
chemokine ligands CCL2, CCL6 and CCL19 which are also thought to play a role in the 
induction of immune responses and IBD (Banks et al., 2003; Otten et al., 2003) were up-
regulated upon inflammation in the double transgenic mice (Fig. 8 E and C). In contrast, 
expression of the chemokine ligands CCL5 and CCL3 were down-regulated (Fig. 8 D 
and F) despite the fact that these ligands are normally found to be highly expressed in 
patients with IBD (Scheerens et al., 2001; Banks et al., 2003). 
Under healthy conditions, LPL show an increased susceptibility to apoptosis related to 
the high expression of FAS antigen and also FAS ligand (De Maria et al., 1996). 
Besides the fact that the percentage of FAS positive LPL is higher when compared to 
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their peripheral T cell counterparts, also upon FAS ligation, cell death is induced more 
effectively in LPL, suggesting that they are “death prone” (De Maria et al., 1996). The 
significance of LPL preprogrammed cell death for intestinal homeostasis is seen in 
conditions in which this homeostasis is disturbed. T cells isolated from areas of 
inflammation in Crohn’s disease, ulcerative colitis and other inflammatory states 
manifest decreased CD2 pathway-induced apoptosis (Boirivant et al., 1999). Differences 
between normal LPL and those generated from inflamed mucosa show that apoptosis-
associated genes such as bax and bcl-2 are differentially expressed in normal versus 
inflamed mucosa. Specifically, increased expression of the anti-apoptitic BCL-2 protein 
was shown (Ina et al. 1999, Itho et al. 2001). The expression level of apoptosis inducers 
and inhibitors is also significantly regulated in mucosal T cells from VILLIN-HA x 
TCR-HA transgenic mice. In LPL, the RNA transcription level of FAS (Tnfsrf6) was 
down-regulated and by decrease of EGR2 in IEL the expression of FAS ligand in 
activated T cells was regulated (Fig. 8 D and F). In addition the expression of the 
mRNA encoding the anti-apoptitic BCL-2 protein by IEL from double transgenic mice 
was significantly up-regulated (Fig. 8 E). Besides genes involved in apoptosis, 
prostaglandins play an important role in the maintenance of the intestinal homeostasis. 
Kabashima et al. (2002) could demonstrate in EP4 knock-out mice that PTGER 4 
suppresses colitis, mucosal damage and CD4+ T cell activation in the gut. In LPL of 
VILLIN-HA x TCR-HA mice the expression level of PTGER4 was decreased which 
indicates an inflammation in the intestine (Fig 8 D). In contrast PTGS1 (COX-1), which 
has been shown to reduce arachidonic acid-induced inflammation and indomethacin-
indiced gastric ulceration (Langerbach et al., 1995), was up-regulated in IEL of diseased 
mice (Fig. 8 E). Constitutive PTGS1 expression is believed to mediate prostaglandin 
dependent gastric protection (Jackson et al., 2000). Tab. 1 summarizes selected genes 
indicating inflammation or regulation in the intestinal mucosa. 
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Table 1: Selected genes differentially expressed in LPL and IEL from VILLIN-HA x TCR-
HA and TCR-HA mice 
 Name  
Regulation  
 
Reference 
 
Cluster 
 
LPL and IEL 
pro-inflammatory 
αΕβ7 
 
↑ Elewaut et al.,1998 A 
 
 S100a6 ↑ Timmons et al., 1993 
 
A 
 Snx9 ↑ Chen et al., 2001 
 
A 
 Tnfrsf7 ↑ Raedler et al., 1985 
Croft, 2003 
A 
 CD83 ↑ te Velde et al., 2003 
 
A 
 Tnfrsf9 ↑ Croft, 2003 
 
A 
LPL 
pro-inflammatory 
Itgb7 ↑ Sun et al., 2001 
Hornquist et al., 1997 
C 
 Itga4 ↑ Ghosh et al., 2003 
Podolsky et al., 2002 
C 
 IL-5 ↑ Fuss et al., 1996 
 
C 
 CCL19 ↑ Otten et al., 2003 
 
C 
 PTGER4 ↓ Kabashima et al., 2002 
 
D 
 CCR6 ↑ Cook et al., 2001 
Varona et al., 2001 
C 
IEL 
pro-inflammatory 
CD7 ↑ Allison et al., 1990 
Trejdosiewicz et al., 1989 
E 
 BCL2 ↑ Ina et al., 1999 
Itoh et al., 2001 
E 
 STAT3 ↑ Lovato et al., 2003 
 
E 
 EGR2 ↓ Lechner et al., 2002 
 
F 
LPL and IEL 
anti-inflammatory 
CST7 ↑ Halfon et al., 1998 A 
 Areg ↑ Troyer et al., 2001 
 
A 
 IL-10 ↑ Van Montfrans et al., 2002 
 
A 
 IFN-γ ↓ Fiocchi, 1998 
 
B 
 IL-7r ↓ Puel et al., 1998 
 
B 
LPL 
anti-inflammatory 
Tnfrsf18/GITR ↑ Shimizu et al., 2002 
Ronchetti et al., 2002 
C 
 LTβ ↓ Agyekum et al., 2003 
 
D 
 Tnfrsf6/FAS ↓ Bregenholt et al., 2001 
Boirivant et al., 1999 
D 
 CCR5 ↓ Agace et al., 2000 
 
D 
 IL-17 ↓ Nielsen et al., 2003 
Fujino et al., 2003 
D 
 ICOS ↓ Kanai et al., 2000 
 
D 
IEL 
anti-inflammatory 
PTGS1/COX1 ↑ Langerbach et al., 1995 
Jackson et al., 2000 
E 
 ANXA1 ↑ Gold et al., 1996 
Vergnolle et al., 1995 
E 
 CCL3 ↓ Banks et al., 2003 
 
F 
 CCR7 ↓ Campbell et al., 2001 
 
F 
 IL-6ra ↓ Ito et al., 2002 
 
F 
 ICAM1 ↓ Ito et al., 2002 
 
F 
 CXCR3 ↓ Yuan et al., 2001 
 
F 
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              continued 
 Name  
Regulation  
 
Reference 
 
Cluster 
 
LPL/IEL 
pro-/anti-inflammatory 
PD1 ↑ Dong et al., 2003 
Salama et al., 2003 
A 
 KLRG1 ↑ Voehringer et al., 2002 
Robbins et al., 2003 
C 
 CCL5 ↓ Scheerens et al., 2002 
 
D 
 Lag3 ↑ Workmann et al., 2003 
 
E 
 Tnfrsf4/OX40 ↑ Murata et al., 2002 
 
A 
 
 
In conclusion, mucosal inflammation in VILLIN-HA x TCR-HA transgenic mice was 
accompanied by brought changes in the gene expression pattern of auto-reactive LPL 
and IEL. The profiling revealed differential expression of pro-inflammatory genes, as 
well as a remarkable set of genes discussed in the context of immune regulation. 
Because of the huge amount of data generated by global gene expression profiling, only 
those genes which are known to be involved in mucosal inflammation or immune 
regulation are discussed here. The entire data set of this microarray experiments is 
accessible as MIAME format online under www.gbf.de/array/download.  
 
3.6 Adoptive transfer of 6.5+CD4+ and 6.5+CD4+depleted of CD25+ T 
cells into VILLIN-HA transgenic mice  
Enterocyte specific IEL from VILLIN-HA x TCR-HA transgenic mice show a reduced 
reactivity to their corresponding antigen and both, LPL and IEL, secrete lower amounts 
of pro-inflammatory cytokines such as IFN-γ and IL-2 upon antigenic stimulation in 
vitro. The mild pathology of mucosal inflammation suggested the induction of 
peripheral tolerance mechanisms, which was further underlined by the gene expression 
pattern of auto-reactive LPL and IEL isolated from the inflamed tissue. The profiling 
data revealed differential expression of pro-inflammatory genes, as well as genes 
discussed in the context of immune regulation and regulatory T cells. Thymic derived 
CD4+CD25+ T cells constitute a major population of regulatory T cells that are able to 
inhibit T cell responses both in vitro (Thornton & Sevach, 1998; Read et al., 1998) and 
in vivo (Suri-Payer et al., 1998; Read et al., 2000). The ability of regulatory T cells to 
control autoimmune diseases has sparked much interest in the question how these cells 
function to control their naïve counterpart. As the data presented here propose the 
induction of regulatory mechanisms preventing an uncontrolled progression of mucosal 
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inflammation in the double transgenic VILLIN-HA x TCR-HA mouse model, it was 
interesting to analyze whether the small proportion of naturally occurring HA-specific 
6.5+CD4+CD25+ regulatory T cells is able to suppress the proliferative and 
inflammatory capacity of 6.5+CD4+CD25- T cells in vivo. Therefore, adoptive transfer 
experiments of 6.5+CD4+ and 6.5+CD4+ T cells depleted from CD25+ cells were 
performed in VILLIN-HA mice. Naïve CD4+ and CD4+CD25- T cells were isolated 
from the spleen of TCR-HA mice by negative selection using the AutoMACS. The 
percentage of 6.5+CD4+ T cells was measured by FACS analysis and CFSE labeling was 
performed. 2 x 106 6.5+CD4+ or 6.5+CD4+CD25- transgenic T cells were injected i.p. 
into VILLIN-HA transgenic mice. 7 days after adoptive transfer the in vivo proliferation 
of transgenic T cells was investigated as judged by the loss of CFSE dye in HA-specific 
CD4+ T cells from spleen, MLN, lamina propria and intestinal epithelium (Fig. 9). 
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Figure 9: Proliferative response of 6.5+CD4+ T cells to tissue derived antigen after adoptive transfer
into VILLIN-HA recipients. 2 x 106 CFSE labeled 6.5+CD4+CD25- or 6.5+CD4+ T cells were adoptively 
transferred into VILLIN-HA recipients. 7 days later cells from spleen, MLN, LP and IE were isolated and 
stained for 6.5 and CD4 expression. CFSE profiles of gated 6.5+CD4+ were estimated.  
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In all compartments investigated a huge proportion of the 6.5+CD4+25- T cells had 
undergone proliferation in response to gut-derived antigen. The proliferation of 
6.5+CD4+ T cells was less prominent suggesting that naturally occurring CD25+ T cells 
suppress antigen specific proliferation of naïve self-reactive CD4+ T cells. To further 
proof this hypothesis the percentage of 6.5+CD4+ transgenic T cells from recipient mice 
was analyzed. As summarized in Fig. 10, the percentage of 6.5+CD4+ T cells was 
increased in spleen, MLN, LP and IE of VILLIN-HA mice that received 6.5+CD4+ T 
cells depleted of the naturally occurring CD25+ T cells. This effect was most impressive 
in the LPL and IEL compartments, strongly suggesting the active repression of 
proliferation of auto-reactive T cells in the gut after antigen encounter by HA specific 
6.5+CD4+CD25+ regulatory T cells. 
 
 
Figure 10: Clonal expansion in 
response to self-antigen. 2 x 106
CFSE labeled 6.5+CD4+ or 
6.5+CD4+CD25- T cells were 
adoptively transferred i.p. into 
VILLIN-HA recipients. 7 days later 
spleen, MLN, LPL and IEL were 
isolated and stained for 6.5 and CD4 
expression to measure the percentage 
of transgenic T cells in the different 
compartments. 
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Taken together, due to inefficient thymic deletion auto-reactive CD4+ T cells migrate to 
the periphery of VILLIN-HA x TCR-HA double transgenic mice. These cells invade the 
lamina propria and the intestinal epithelium where they encounter their specific antigen. 
Antigen contact does not result in uncontrolled inflammation, but in a chronic form of 
mild enterocolitis, suggesting the induction of peripheral tolerance mechanism 
counteracting inflammatory processes in the mucosa. These mechanisms obviously 
include a reduced proliferative capacity of intestinal lymphocytes, changes in the 
cytokine pattern, as well as brought changes in the gene expression profile of auto-
reactive CD4+ T cells from the inflamed gut. In addition, naturally occurring 
CD4+CD25+ T cells also seem to be involved in the maintenance of the immunological 
balance, as they inhibit proliferation of auto-reactive CD4+ T cells in an antigen specific 
manner. 
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4 Discussion 
The gastrointestinal tract is home to the largest number of lymphocytes in the body as 
well as being the site where these cells encounter abundant exogenous stimuli. 
Regulation of the immune response in the intestine is a balance between the need to 
mount protective immunity towards pathogens and unresponsiveness to harmless 
antigens present in the intestine, including those derived from resident bacteria. The 
development of inflammatory bowel disease, encompassing Crohn’s disease and 
ulcerative colitis, provides a dramatic illustration of the consequence of a breakdown in 
intestinal immune regulation. Basic and clinical studies demonstrated, that IBD share 
some characteristics with autoimmune diseases, since autoantibodies have been detected 
in human patients and autoimmune mechanisms clearly contribute to the disease in mice 
(Mizoguchi et al., 1996; Shanahan et al., 1992). Inappropriate T cell responses towards 
harmless antigens are responsible for the chronic inflammatory processes leading to 
intestinal inflammation (Podolsky, 2002; Strober et al., 2002) due to the observation that 
T cell accumulation in the inflamed tissue occurs. 
Mucosal inflammation and tissue damage is predominately mediated by cellular lysis 
and secretion of perforin by CD8+ T cells (Kagi et al., 1995; Kagi et al., 1996). 
Additionally, the secretion of inflammatory cytokines like TNF-α potentiates the 
inflammatory process by enhancing infiltration of mononuclear cells. More recently it 
was shown that CD4+CD45RBhigh T cells are capable to initiate an intestinal 
inflammation in lymphopenic mice (Dohi et al., 2003). Responsible for regulation and 
control of the intestinal inflammatory processes are different types of regulatory T cells, 
Th3 cells, CD4+CD25+ or CD4+CD45RBlow T cells or CD8+ suppressor T cells (Miller 
et al., 1992; Sakaguchi et al., 2000; Roncarolo & Levings, 2000; Mowat, 1987). These 
regulatory cells induce immunosupression in surrounding T cells most likely by 
secretion of regulatory cytokines such as IL-10 or TGF-β and inhibit inappropriate 
immune responses towards harmless mucosal antigens (Ludviksson et al., 2000; Strober 
et al., 1998). 
Despite the fact that T cells with an autoaggressive character are involved in the 
development of intestinal inflammation, it has been difficult to identify self-proteins that 
may play a role in the etiology or chronicity of IBD and to asses the impact of antigen-
specificity. An important aim of this study was to test the hypothesis that antigen-
specific CD4+ T cell recognition of a single epithelial self antigen is sufficient to trigger 
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an inflammatory cascade resulting in histological manifestation in the intestine and 
investigate whether regulatory mechanisms may suppress inflammation and maintain 
homeostasis. To analyze the immunological and molecular mechanisms of antigen 
specific CD4+ T cell response in chronic mucosal inflammation, a transgenic mouse 
expressing hemagglutinin (HA) in enterocytes of the intestinal epithelium was generated 
(Templin et al., submitted). Concomitant expression of HA and a MHC class II-
restricted T cell receptor specific for HA in VILLIN-HA x TCR-HA mice resulted in an 
autoimmune mediated chronic intestinal inflammation.  
 
Autoimmune diseases are believed to be under complex genetic regulation, but all 
require some form of escape from self-tolerance. In VILLIN-HA x TCR-HA double 
transgenic mice 6.5+CD4+ transgenic T cells could be detected in the peripheral 
lymphatic organs including spleen and MLN (Fig. 1). This finding was not unexpected, 
as it has been described previously that expression of the HA-antigen in pancreas 
(Degermann et al., 1994; Sarukhan et al., 1998) and in hematopoetic cells (Lanoue et al., 
1997) of INS-HA x TCR-HA and IgHA x TCR-HA double transgenic mice does not 
lead to complete deletion of 6.5+ T cells. A possible explanation for the escape from 
central tolerance might involve coexpression of two different T cell receptors by the 
same cell. Due to allelic inclusion of TCRα genes self-reactive T cells may leave the 
thymus resulting in induction of autoimmunity in the periphery (Sarukhan et al., 1998). 
To exclude that self-reactive peripheral T cells were rendered in an anergic state, we 
compared the proliferative capacity of transgenic T cells from single and double 
transgenic mice. Enterocyte-specific expression of HA in VILLIN-HA x TCR-HA did 
not lead to tolerance induction in the periphery as no differences in their capacity to 
proliferate upon stimulation with their cognate peptide could be observed (Fig. 2). Flow 
cytometry analysis revealed that 6.5+CD4+ T cells from VILLIN-HA x TCR-HA 
exhibited an activated phenotype since frequencies of 6.5+CD4+ T cells expressing the 
activation markers CD69 and CD25 in spleen and MLN of these mice were significantly 
increased as well as the expression of CD45RB and CD62L was reduced (Fig. 3), 
indicating that HA-specific CD4+ T cells encountered their specific antigen which is 
expressed exclusively by intestinal epithelial cells. 
 
Immunohistochemistry of the intestine of VILLIN-HA x TCR-HA double transgenic 
mice was performed to estimate the grade of intestinal inflammation. As demonstrated 
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in Fig. 4, double transgenic mice showed a mild autoimmune enterocolitis. This was 
accompanied by infiltration of CD3+ lymphocytes in the LPL and IEL compartment and 
development of lymph edema. However, tissue damage to the epithelial layer could not 
be observed, indicating that the immunological balance in double transgenic mice stands 
on the edge, where on the one hand activation and infiltration of lymphocytes in the 
intestine occurs, but on the other hand regulatory mechanisms seem to counteract 
uncontrolled progression of intestinal inflammation. 
 
To characterize the inflammatory processes in the intestine of VILLIN-HA x TCR-HA 
mice in more detail 6.5+CD4+ LPL and IEL were analyzed according to their 
proliferative capacity upon antigenic stimulation and secretion of pro- or anti-
inflammatory cytokines. When mucosal lymphocytes are stimulated via the T cell 
receptor they normally respond only poorly and activation seems to be dependent on 
CD2/CD28 stimulation to result in proliferation and cytokine secretion (Boirivant et al., 
1999; Targan et al., 1995). Interestingly, IEL and LPL from TCR-HA mice as well as 
LPL from VILLIN-HA x TCR-HA transgenic mice proliferate in an antigen dose 
dependent manner. In contrast, the specific proliferative capacity of IEL from double 
transgenic mice was abrogated with a high background proliferation even without 
antigenic stimulation, thus resembling the normal phenotype of mucosal lymphocytes 
(Fig. 5). The cytokine profile in inflammatory bowel disease shows some characteristic 
differences depending on the kind of disease. Crohn’s disease is associated with a TH1 
cytokine pattern, characterized by INF-γ, TNF-α, and IL-12 secretion (Fiocchi, 1998; 
Elson, 2000). In ulcerative colitis, the cytokine profile is less restricted, it is not 
resembling a TH1 response and appears to be a modified TH2 response associated with 
cytokines such as IL-5 and IL-10 (Fiocchi, 1998; Sands, 2000). In the VILLIN-HA x 
TCR-HA transgenic mouse model antigen stimulated 6.5+CD4+ LPL and IEL from 
diseased mice secreted lower amounts of INF-γ and IL-2 upon in vitro stimulation 
compared to control mice (Fig. 6 and 7). These data suggested a suppression of pro-
inflammatory mediators in the intestine of double transgenic mice. However, the basal 
level secretion of TNF-α, MCP-1, and IL-6, which are all important mediators in the 
induction of IBD, was considerably increased in LPL and IEL from double transgenic 
mice (Fig. 6 and 7). This disagreement in the cytokine secretion of transgenic LPL and 
IEL from VILLIN-HA x TCR-HA mice may denote a steady state between regulatory 
and pathological mechanisms being active in the intestine. To consider this hypothesis 
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in more detail, global gene expression analysis of HA-specific LPL and IEL which were 
isolated directly from the intestine of VILLIN-HA x TCR-HA mice or from TCR-HA 
control mice was performed. 
 
A heterogeneous set of genes differentially expressed in auto-reactive CD4+ T cells was 
identified. As expected, many of the genes found to be regulated have been described 
earlier in the context of intestinal inflammation. Some pro-inflammatory genes were 
specifically regulated in both LPL and IEL. In agreement with published data, the 
integrin αΕβ7 expression was up-regulated in 6.5+CD4+ LPL and IEL from inflamed 
tissue of VILLIN-HA x TCR-HA transgenic mice when compared with cells form 
control mice. It has been shown that changes of αΕβ7 expression in Crohn’s disease and 
ulcerative colitis patients versus controls are of pathological relevance and that this may 
be one of the earliest events in the pathogenesis of this disease (Elewaut et al., 1998). A 
wide variety of members of TNF receptor superfamily were differentially expressed on 
LPL and IEL from double transgenic mice. Especially, Tnfrsf7 and Tnfrsf9 were up-
regulated on LPL and IEL from inflamed tissue. This molecules are known to be 
expressed in elevated numbers of peripheral lymphocytes in inflammatory bowel disease 
(Raedler et al., 1985; Croft, 2003). LPL and IEL do not resemble a homogenous T cell 
population, each population has an own phenotype with specialized function. According 
to this characteristics, the gene expression profile of these cells may differ. Indeed, 
many genes were found to be exclusively regulated in LPL of VILLIN-HA x TCR-HA 
transgenic mice. Although αΕβ7 was up-regulated in both LPL and IEL, expression of 
various other integrins was significantly increased only in LPL from inflamed tissue. 
Integrins are involved in lymphocyte homing to the intestinal mucosa and it has been 
demonstrated that their expression is often enhanced upon intestinal inflammation (Sun 
et al., 2001; Hornquisst et al., 1997; Podolsky et al., 1993). Also IL-5 secretion was 
significantly up-regulated in LPL from VILLIN-HA x TCR-HA mice. This cytokine 
plays a key role in the induction of ulcerative colitis (Fuss et al., 1996). Besides genes 
exclusively regulated in LPL, many pro-inflammatory genes exist, which expression 
level is only changed in the IEL of double transgenic mice. One example is the 
expression of the CD7 surface molecule. In line with published data which show that the 
frequency of CD7+ T cells is significantly increased in inflammatory bowel disease, the 
expression of CD7 in IEL of VILLIN-HA x TCR-HA mice was up-regulated. In 
addition, the expression level of STAT 3 was increased in IEL. STAT3 has been shown 
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to be directly linked to secretion of IL-6 in inflammatory bowel disease (Wang et al., 
2003). This is in accordance with the finding that LPL and IEL from VILLIN-HA x 
TCR-HA secrete higher amounts of IL-6 compared to control cells (Fig. 8). Intestinal 
inflammation is often initiated by a failure of mucosal lymphocytes to undergo 
preprogrammed cell death (De Maria et al., 1996) In agreement with this, the anti-
apoptotic bcl-gene expression was significantly up-regulated in IEL of the inflamed 
tissue. In addition, a decreased EGR2 expression level was found in IEL from double 
transgenic mice, a factor known to expression of FAS ligand in activated T cells 
(Lechner et al., 2001). Many other genes were found to be significantly up- or down-
regulated in the inflamed intestine when compared with healthy donors, such as CD83, 
CCL19, PTGER4 or CCR7 and numerous others which have been discussed in the 
context of inflammatory bowel disease (te Velde et al., 2003; Otten et al., 2003; 
Kabashima et al., 2002; Campbell et al., 2001). 
In addition to genes that are associated with intestinal inflammation, also a large number 
of genes previously been described to play a role in immune regulation in the intestine 
have been identified. The major finding was, that the expression of IL-10 and IFN-
γ, both of which are mediators playing important roles in the regulation of progression 
of IBD, were significantly regulated in IEL and LPL of diseased mice. IL-10 was highly 
up-regulated in LPL and IEL from double transgenic mice compared to control mice. 
Using a murine knock-out model it has been shown, that IL-10 prevents the 
development of intestinal inflammation (Kuhn et al., 1993). Furthermore, the 
application of IL-10 to diseased mice abrogated clinical signs or suppressed the 
inflammation in the intestine (Steidler et al., 2000). In addition, INF-γ, which plays a 
key role in the induction of IBD, was down-regulated in mucosal lymphocytes of 
VILLIN-HA x TCR-HA transgenic mice. Furthermore, the expression of other pro-
inflammatory cytokine like LT-β and IL-17 in LPL from double transgenic mice was 
also down-regulated. Recently, it has been shown that Tnfrsf18 (GITR) is 
predominantly expressed on CD4+CD25+ regulatory T cells (Shimizu et al., 2002). This 
member of the TCR receptor superfamily was significantly up-regulated in LPL of 
double transgenic mice. Also IEL showed differential gene expression resembling the 
induction of regulatory mechanisms to maintain homeostasis. Constitutive PTGS1 
expression is believed to mediate prostaglandin dependent gastric protection (Jackson et 
al., 2000). In IEL of VILLIN-HA x TCR-HA transgenic mice, prostaglandin expression 
was up-regulated. In contrast, genes involved in IBD induction like CCR7, IL-6a or 
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ICAM were down-regulated in IEL. In summary, mucosal inflammation in the intestine 
of VILLIN-HA x TCR-HA transgenic mice was accompanied by brought changes in the 
gene expression pattern of LPL and IEL. Profiling revealed differential expression of 
pro-inflammatory genes, as well as a remarkable set of genes discussed in the context of 
immune regulation.  
 
The mild form of mucosal inflammation suggested the induction of peripheral tolerance 
mechanisms, a hypothesis which was further underlined by the gene expression pattern 
of LPL and IEL from VILLIN-HA x TCR-HA transgenic mice. The induced expression 
of a wide variety of genes involved in regulatory processes suggested the induction of 
regulatory T cells in the intestine counteracting the uncontrolled progression of 
autoimmune disease. In addition to Treg cells induced in an antigen-specific manner in 
the periphery of double transgenic mice, every individual harbors a small population of 
naturally occurring, thymus derived CD4+CD25+ T cells that are able to inhibit T cell 
responses both in vitro (Takahashi et al., 1998; Read et al., 2000) and in vivo (Suri-
Payer et al., 1998; Read et al., 2000). Adoptive transfer experiments into VILLIN-HA 
transgenic mice demonstrated that this small proportion of naturally occurring 
regulatory T cells was sufficient to reduce the profilerative capacity of naïve transgenic 
T cells in vivo (Fig. 9). In most of the published transfer experiments done to 
characterize the properties of regulatory T cells, the hosts are lymphopenic and the 
transferred T cell subsets are polyclonal with unknown antigen specificity (Asseman et 
al., 2003; Maloy et al., 2003;). Therefore, physiological regulatory functions cannot be 
distinguished easily from effects that are caused by homeostatic proliferation and clonal 
expansion of transferred cells (Bach, 2003; Barthlott et al., 2003). Transfer experiments 
into VILLIN-HA mice are based on the use of animals with an intact immune cell 
repertoire. Thus, the results summarized in Fig. 10 demonstrated that the effect of 
transferred T cells on antigen specific proliferation and clonal expansion is due to 
suppressor function of Treg cells and not a result of homeostatic proliferation in a 
lymphopenic host. Furthermore, as the transferred T cells represent a monoclonal subset 
with known antigen specificity to an autoantigen, the obtained results resemble an 
interaction between antigen induced regulatory T cells and naturally occurring Treg cells 
in the VILLIN-HA x TCR-HA double transgenic mouse model.  
Further studies are needed to clarify the role of regulatory T cells in the development of 
chronic intestinal inflammation in VILLIN-HA x TCR-HA transgenic mice. The mild 
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chronic intestinal inflammation represents an unbalance between inflammatory 
processes and mucosal immune regulation. These data provide novel insights into 
pathogenic mucosal T cell responses in chronic intestinal inflammation and will permit 
to carefully dissect the mechanisms by which enterocyte specific LPL and IEL regulate 
or prime intestinal inflammation.  
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5 Summary 
Chronic inflammatory bowel disease could be the consequence of an antigen specific 
dysregulated T cell response with the expansion of T cells and the induction of 
immunopathology. The immunological and molecular mechanisms of antigen specific 
CD4+ T cell response in chronic mucosal inflammation was analyzed using a transgenic 
mouse expressing hemagglutinin (HA) in enterocytes of the intestinal epithelium. 
Concomitant expression of HA and a MHC class II-restricted T cell receptor specific for 
HA resulted in an autoimmune mediated chronic inflammation. This inflammation was 
accompanied by activation of peripheral HA specific lymphocytes and lymphocytic 
infiltration in the lamina propria and intestinal epithelium. The mild form of mucosal 
inflammation suggested the induction of peripheral tolerance mechanisms. These 
mechanisms were studied in more detail. Extensive immunological characterization of 
self reactive LPL and IEL isolated from the inflamed intestine was performed by 
cellular assays and global gene expression profiling. Enterocyte specific LPL show a 
dose dependent proliferative response upon antigenic stimulation, whereas the 
proliferative capacity of IEL was reduced. After in vitro stimulation, mucosal 
lymphocytes from diseased secreted lower amounts of the pro-inflammatory cytokines 
INF-γ and IL-2, but the secretion of TNF-α, MCP-1 and IL-6 was increased. Moreover, 
mucosal inflammation was accompanied by brought changes in the gene expression 
pattern of LPL and IEL. The profiling revealed differential expression of pro-
inflammatory genes, as well as a remarkable set of genes discussed in the context of 
immune regulation. Transfer of naïve 6.5+CD4+ and 6.5+CD4+CD25- transgenic T cells 
into VILLIN-HA transgenic mice demonstrated the regulatory potential of the small 
proportion of naturally occurring CD4+CD25+ T cells, that might act in concert with 
peripherally induced regulatory T cells to prevent uncontrolled progression of the 
disease. The VILLIN-HA x TCR-HA double transgenic mouse model will permit to 
carefully dissect the mechanisms by which enterocyte specific LPL and IEL regulate or 
prime a chronic intestinal inflammation and to identify target molecules useful for 
therapeutic approaches in the field of intestinal diseases. 
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Modulation of mucosal immune response using bacterial cell 
surface display of a functional T cell epitope  
 
1 Background 
IBD models support a central role for dysregulated CD4+ T cell response to enteric 
bacterial flora as a common disease mechanism. The mechanisms by which the bacterial 
flora stimulates colitis in susceptible hosts is unknown and is likely to be multifactorial. 
A recent study showed that colitis can be caused by reconstituting SCID mice with 
CD4+ T cell lines established from C3H/HeBir mice exposing the mice to their fecal 
extracts (Brimnes J. et al., 2001). Additionally, reconstitution of SCID mice with naïve 
CD4+ T cells specific to OVA or the transfer of those cells into BALB/c mice followed 
by colonization of these mice with OVA expressing E.coli led to wasting disease 
(Yoshida et al., 2001; Yoshida et al., 2002). In contrast, Iqbal et al. (2002) published a 
colitis model based on the use of  OVA-producing E.coli and the transfer of TH1 or TH2 
OVA-specific CD4+ T cells into RAG2-/- mice. No colitis was observed in mice that 
received naïve CD4+ T cells specific for the antigen produced by luminal E.coli in the 
intestine. Thus, different mouse models used to study the role of bacterial antigen on the 
induction of IBD lead to controversial results. Growing evidence suggests that 
inflammatory bowel disease may be associated with a dysregulated mucosal immune 
response towards indigenous microbial antigens in a genetically susceptible host with 
the breakdown of epithelial integrity or loss of tolerance (Elson et al., 1995; Strober et 
al., 1998). However, it has been shown that not all members of the microflora are 
necessarily pathogenic in IBD. Evidence has emerged that probiotics ameliorate, rather 
than induce inflammation (Madsen et al., 1999). Possible mechanisms of probiotic 
action in inflammatory bowel disease include the production of antimicrobial factors, 
competitive interaction with pathogens, and crosstalk with the host epithelium 
(Shanahan, 2000). Thus, on the one hand the intestinal microflora including probiotics 
have beneficial effects on the host immunity and on the other hand bacteria present in 
the gut lumen are able to induce gut inflammation. These findings highlight the 
existence of a sensitive balance between anti- and pro-inflammatory factors in the gut.  
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2 Aims of the study 
To investigate the possibility of influencing the immunological balance in the intestine 
by manipulation of the microflora with bacteria expressing a specific antigen, the 
probiotic E.coli NISSLE 1917 strain was transformed to express the HA110-120 peptide 
at the bacterial surface. To answer the question, whether CD4+ T cells specific for the 
bacterially expressed HA in the mouse gut have the potential to initiate 
immunopathogenic mechanisms leading to mucosal inflammation, extensive analyses on 
the interaction of bacterial associated antigen in the intestine and HA-specific CD4+ T 
cells should be performed: 
 
• Characterization of the antigenic potential of E.coli NISSLE-HA110-120 in vitro as  
   well as in vivo. 
 
• Determination of the impact of bacterial antigen expression in the intestine on 
migration, activation and clonal expansion of antigen specific CD4+ T cells. 
 
• Studies should be performed in TCR-HA, BALB/c, as well as in lymphopenic RAG1-/- 
mice adoptively transferred with antigen-specific CD4+ T cells.  
 
• To define the role of an intact epithelial barrier on the modulatory effect of E.coli 
NISSLE, experiments should be carried out in healthy mice with a completely intact 
barrier or in diseased mice with a defect intestinal barrier obtained by the treatment 
with chemically agents.  
 
• Finally, the potential of E.coli NISSLE as carrier organism for gut specific delivery of 
biological important molecules in the context of intestinal inflammation should be 
studied. 
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3 Results 
3.1 Generation and characterization of E.coli NISSLE 1917 
expressing the HA110-120 peptide at their surface  
To study the influence of luminal bacterial antigen on the development of a mucosal T 
cell response in the mouse intestine, bacteria were generated which express a specific 
antigen at their surface. For efficient export and surface expression of passenger proteins 
through the inner and outer bacterial membrane the adhesin-involved-in-diffuse-
adherence (AIDA) autotransporter system was used. The AIDA autotransporter is 
synthesized as precursor comprising of a N-terminal leader peptide (SP) that targets the 
protein to the periplasm, the C-terminal AIDAc, which inserts into the outer membrane 
and transports the N-terminally linked AIDA-I to the bacterial surface (Konieczny et al., 
2000). The MHC class II HA110-120 epitope of the influenza virus A/PR/8/34 (HA) 
was incorporated into permissive sites of the AIDAc translocator module (Fig. 1A). The 
construction of the HA110-120/AIDA fusion protein should result in the surface display 
of the HA110-120 peptide (Fig. 1B). The plasmid harboring the gene for the AIDA 
autotransporter protein also encodes for an ampicillin resistance gene. As bacterial 
carrier strain E.coli NISSLE 1917 was chosen. This apathogenic strain is part of the 
commensal microflora, it is characterized by its excellent colonization properties in the 
gut and is used as probiotics in the biological therapy of intestinal disease.  
To assess the functionality of the AIDA autotransporter system for the surface 
expression of the HA110-120 epitope, immunolabeling experiments were done. E.coli 
NISSLE-HA110-120 were surface labeled with mouse antibody raised against the 
HA110-120 epitope and a goat anti mouse CyTM3 conjugated secondary antibody. 
Fluorescence microscopy showed that E.coli NISSLE-HA110-120 expressed the 
antigenic epitope at their surface (Fig. 1C I). E.coli NISSLE transformed with a plasmid 
encoding for the AIDA autotransporter served as negative control (Fig. 1C II). An 
important question to answer was whether the presentation of the HA110-120 T cell 
epitope at the surface of bacteria would result in the stimulation of corresponding T cells 
in vitro. To this end, peritoneal macrophages were exposed to E.coli NISSLE-HA110-
120 and than tested in vitro for stimulation of TCR-HA transgenic T cells. As shown in 
Fig. 1D, HA-specific T cells proliferated in vitro in response to macrophages pulsed 
with bacteria expressing the HA110-120 peptide, but not with control bacteria. Taken 
together, transformed E.coli NISSLE produced the HA110-120 peptide and presented 
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this epitope at their surface. This epitope is potently immunogenic for TCR-HA T cells 
in vitro. 
 
 
AIDA-I
AIDAc
om
HA110-120
AIDA-I AIDAc
cleavage by
sec system
COOHNH2
HA110-120-epitope
0
5
10
15
20
25
30
35
40
45
50
8 80 800
Bacteria (CFU x 102)
Pr
ol
ife
ra
tio
n
(c
pm
x
10
3 )
II
III
IV
I
 
D
B
C 
A 
 
 
 
 
 
 
 
 
I
 
T
e
h
 n vivo immunogenicity of HA110-120 expressing E.coli NISSLE 
Figure 1: Expression and immunogenicity of the MHC class II peptide HA110-120. (A) Schematic 
representation of the AIDA (adhesine involved in diffuse adherence) autotransporter and the use of this 
autotransporter for the presentation of the HA110-120 peptide at the surface of E.coli NISSLE. HA110-
120 was integrated into the extracellular part of the AIDAc domain. (B) Model of the integration of 
AIDAc in the outer membrane and transport of the N-terminally linked AIDA-I and the integrated 
HA110-120 to the bacterial surface. (C) Immunofluorescence microscopy of E.coli NISSLE-HA110-
120 (I) and E.coli NISSLE control strain (II) using an antibody specific for the HA110-120. III and IV
show the phasecontrast of the transformed E.coli NISSLE. (D) Proliferation of HA110-120 specific T 
cells. Peritoneal cells were incubated with HA expressing bacteria for 5 h. Thereafter, HA specific T 
cells were added in medium containing antibiotics. After 48 h T cells were labeled with 3[H]-thymidine 
and proliferation was measured by thymidine incorporation.  he most important requirement for the use of E.coli NISSLE-HA110-120 to study the 
ffect of bacterial antigen expression on the mucosal immune system is that the bacteria 
ave the potential to stimulate a specific T cell response. The capacity of recombinant 
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E.coli NISSLE-HA110-120 to stimulate TCR-HA transgenic T cells in vivo was 
assessed by adoptive transfer experiments. BALB/c mice that received 2.5 x 106 CFSE 
labeled TCR-HA CD4+ T cells were inoculated i.p. with either PBS, 108 control E.coli 
NISSLE or 108 E.coli NISSLE expressing the HA110-120 peptide. Two days later the in 
vivo proliferation of TCR-HA transgenic T cells was measured in spleen and MLN by 
loss of CFSE labeling. Injection of HA110-120 expressing bacteria resulted in a 
complete loss of CFSE in nearly all HA-specific T cells in spleen and MLN, indicating 
that the HA expressing bacteria are able to stimulate a HA-specific CD4+ T cell 
response in vivo (Fig. 2). Injection of PBS and control bacteria also resulted in T cell 
proliferative response but to a significant lower extend. These data indicate that the 
E.coli NISSLE-HA110-120 have the potential to stimulate antigen specific responses in 
vitro as well as in vivo. 
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 Figure 2: In vivo proliferation of HA-specific CD4+ T cells after injection of HA110-120 expressing
E.coli NISSLE. BALB/c recipients of CFSE labeled HA-specific CD4+ T cells were injected i.p. with
PBS (left panels), 108 control E. coli NISSLE (middle panels) or 108 E. coli NISSLE-HA110-120 (right
panels). Two days later splenocytes and mesenteric lymph node cells were stained with anti-CD4 and
anti-6.5. 6.5+CD4+ cells were gated and the CFSE labeling of the transgenic cells is shown as histogram. 3.2 Characterization of the primary T cell response induced in vivo by 
E.coli NISSLE expressing the HA110-120 peptide in the gut 
o directly evaluate the influence of bacterial antigen expression in the gut lumen on the 
orresponding transgenic T cells in vivo TCR-HA mice were colonized with E.coli 
ISSLE-HA110-120 or control bacteria by a single oral application of 2 x 1015 CFU per 
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mouse. To ensure stable colonization of the intestine, 0.3 mg/ml ampicillin were added 
to the drinking water of the mice and the CFU/g feces were determined during the time 
of the experiment. Two weeks after oral application of the bacteria the mice were 
sacrificed and the percentage of HA-specific 6.5+CD4+ T cells in spleen, MLN, LPL, 
and IEL was analyzed (Fig. 3).  
 
 
Figure 3: E.coli NISSLE expressing the 
HA110-120 peptide in the gut of TCR-HA 
mice do not induce expansion of HA-
specific CD4+ T cells. TCR-HA mice were 
inoculated either with E.coli NISSLE or 
E.coli NISSLE-HA110-120. After two weeks 
the mice were sacrificed and flow cytometry 
was done to determine the percentage of 
transgenic T cells in spleen, MLN, LPL and 
IEL.  
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In all compartments tested no significant differences in the percentage of transgenic T 
cells could be observed in mice colonized with E.coli NISSLE-HA110-120 compared to 
the control strain, indicating that luminal antigen expression obviously did not result in 
clonal expansion of 6.5+CD4+ T cells and also not in increased migration of HA-specific 
CD4+ T cells to the intestine. TCR stimulation should result in up-regulation of CD25 
and CD69 as well as down-regulation of CD45RB and CD62L. To investigate, whether 
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transgenic T cells are activated by luminal bacteria expressing the HA110-120 peptide, 
the activation status of HA-specific transgenic T cells was assessed (Fig. 4).  
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 Figure 4: HA-specific CD4+ transgenic T cells from colonized TCR-HA mice showed no changes 
in the activation pattern. TCR-HA mice were inoculated either with E.coli NISSLE or E.coli
NISSLE-HA110-120. After two weeks the mice were sacrificed and flow cytometry on 6.5+CD4+ gated 
cell from spleen (A) and MLN (B) was done to determine activation profile.   
 
HA-specific T cells in spleen and MLN of colonized TCR-HA mice showed no changes 
in the expression of CD45RB, CD69, CD25 and CD62L when comparing the phenotype 
of cells isolated from mice colonized with E.coli NISSLE-HA110-120 and control 
bacteria. To exclude the possibility that the observed unresponsiveness of transgenic T 
cells is due to inappropriate duration of the colonization periods, a kinetic was done 
including colonization of TCR-HA mice for one, two, three and four weeks as well as 
for 6 month. In any case, no significant effect of bacterial antigen expression in the gut 
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on migration, clonal expansion and the activation status of HA-specific CD4+ T cells 
could be observed. 
 
3.3 Bacterial colonization of BALB/c mice adoptively transferred with 
HA-specific CD4+ did not result in clonal expansion of 6.5+CD4+ 
transgenic T cells 
Naïve HA-specific CD4+ cells continuously mature in the thymus of TCR-HA mice 
which then migrate into peripheral organs. This naïve T cells might conceal the 
activated phenotype of a comparably small number of antigen experienced T cells. To 
exclude that this fact might be responsible for an undetectable immune response to the 
bacterially expressed antigen in TCR-HA mice, adoptive transfer of a defined amount of 
6.5+CD4+ transgenic T cells into BALB/c mice was done. 2 x 106 transgenic T cells 
were transferred i.p. into BALB/c mice followed by the colonization of the recipients 
with E.coli NISSLE-HA110-120 or the control strain. At day 7 after oral application of 
bacteria the mice were sacrificed and the percentage of transgenic T cells in spleen and 
MLN was measured, as a proliferative response of 6.5+CD4+ transgenic T cells should 
result in an increase of transgenic T cell numbers. However, no significant differences in 
the number of transgenic T cells in spleen and MLN could be detected in the E.coli 
NISSLE-HA110-120 colonized mice when compared to control mice (Fig. 5 ). 
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Figure 5: Adoptive transfer of HA-
specific CD4+ T cells into BALB/c mice 
colonized with E.coli NISSLE-HA110-
120 did not lead to clonal expansion of 
6.5+CD4+ transgenic T cells. BALB/c 
mice were injected i.p. with 2 x 106
transgenic CD4+ T cells and  recipients 
were inoculated with E.coli NISSLE or 
E.coli NISSLE-HA110-120. 7 days later 
two-color flow cytometric analysis was 
performed on spleen and MLN cells. The 
percentage of 6.5+CD4+ T cells in the 
lymphocyte gate was determined. 
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3.4 Transfer of in vitro activated HA-specific CD4+ T cells into 
BALB/c mice and colonization with E.coli NISSLE-HA110-120 
did not result in antigen specific immune response 
Naïve T cells need a certain antigen threshold for the induction of an immune response 
against the specific antigen. To exclude the possibility that the antigen concentration 
produced by the orally applied bacteria in the murine gut was too low to activate T cells, 
in vitro activated HA-specific CD4+ T cells were used for an adoptive transfer to abate 
the stimulus threshold. Therefore splenocytes of TCR-HA mice were activated with the 
corresponding HA110-120 peptide for 4 days in culture and the percentage of transgenic 
T cells as well as their activation status was measured by flow cytometry. 40 % of the 
splenocytes in culture were 6.5+CD4+ T cells and showed an activated phenotype as 
indicated by the expression of CD69 and CD25 as well as down-regulation of CD45RB 
(Fig. 6). 
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Figure 6: Activated phenotype of 6.5+CD4+ T cells after in vitro stimulation. Splenocytes of TCR-
HA mice were isolated and activated with 10 µg/ml HA110-120 peptide. After 4 days dead cells were 
removed by ficoll gradient centrifugation and the viable cells were cultured an additional day. Flow 
cytometric analysis was performed to determine the percentage of 6.5+CD4+ cells in the lymphocyte 
population and the activation state of the HA-specific T cells. Histograms were obtained after gating on 
6.5+CD4+ T cells. 
 
 
BALB/c were injected i.p. with 6 x 106 activated 6.5+CD4+ transgenic T cells and 
colonized with E.coli NISSLE-HA110-120 or control bacteria. 14 days after adoptive 
transfer and bacterial colonization the percentage of transgenic T cells was measured in 
spleen and MLN by flow cytometry. No differences in the percentage could be detected 
independent of the bacterial strain used for the colonization. 0.39 % TCR-HA transgenic 
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T cells were found in the spleen and about 0.7 % in the MLN of BALB/c mice 
previously transferred with activated 6.5+CD4+ transgenic T cells (Fig. 7A). The 
activation profile of the transgenic T cells was identical when comparing colonization of 
transferred mice with E.coli NISSLE-HA110-120 and the E.coli NISSLE control strain 
(Fig. 7B). As expected, the activation marker CD69 and CD25 were down-regulated two 
weeks after transfer. Cells showed a memory T cell phenotype indicated by low 
expression levels of the CD45RB molecule. Thus, also the adoptive transfer system 
using activated HA-specific T cells did not support the idea, that luminal antigen 
produced by bacteria might result in the stimulation of a specific T cell response in 
mice. 
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 Figure 7: Transfer of in vitro activated 
HA-specific CD4+ T cells into BALB/c 
mice and colonization with E.coli
NISSLE-HA110-120 does not  lead to 
detectable immune responses. BALB/c 
mice were injected i.p. with 6 x 106
activated HA specific CD4+ T cells and 
recipients were inoculated with E.coli
NISSLE or E.coli NISSLE-HA110-120.
After two weeks flow cytometric analysis 
was performed on spleen and MLN to 
determine to percentage of 6.5+CD4+
transgenic T cells (A) and their activation 
pattern (B). 25
0-120  
CHAPTER III  70 
3.5 Adoptive transfer of HA-specific CD4+ T cells into E.coli NISSLE-
HA110-120 colonized RAG-1-/- mice does not induce clonal 
expansion of transgenic T cells. 
It was hypothesized that the balance of the peripheral immune system might be a side 
effect of normal competition. To clarify whether this natural competition prevents an 
immune response to the bacterial derived specific antigen in this model, 107 transgenic 
CD4+ T cells were injected i.p. into RAG-1-/- mice and recipients were orally inoculated 
with E.coli NISSLE-HA110-120 or E.coli NISSLE control bacteria. RAG1-/- mice are 
lymphopenic, i.e. these mice lack the T and B cell populations. Three weeks after 
transfer and bacterial colonization flow cytometric analysis was performed on 
splenocytes and MLN of the recipient mice. No differences in the percentage of 
transgenic T cells could be observed in mice colonized with E.coli NISSLE-HA110-120 
compared to the control animals. In the spleen 11 % and in the MLN 33 % to 37 % of 
the recovered lymphocytes were 6.5+CD4+ transgenic T cells. Thus, the normal 
competition is not the cause of failure of immune response against antigens of bacterial 
gut flora. 
 
 
Figure 8: Adoptive transfer of HA-
specific CD4+ T cells into bacterial 
colonized RAG-1-/- mice does not lead to 
antigen specific clonal expansion of 
transgenic T cells. RAG-1-/- mice were 
injected i.p. with 1 x 107 6.5+CD4+
transgenic T cells and recipients were 
inoculated with E.coli NISSLE or E.coli
NISSLE-HA110-120. After three weeks 
flow cytometric analysis was performed on 
spleen and MLN to determine to 
percentage of 6.5+CD4+ transgenic T cells. 
6.5
Sp
le
en
M
LN
11.0%
33.1% 37.4%
11.5%
E.coli
NISSLE
E.coli
NISSLE-HA110-120
 
 
 
CHAPTER III  71 
3.6 Treatment of RAG1-/- mice reconstituted with HA-specific CD4+ T 
cells with DSS and bacterial colonization did not induce an 
antigen specific immune response 
A variety of mechanisms contribute to the ability of the gut to either react or remain 
tolerant to antigen present in the intestinal lumen. The epithelial cells form a barrier 
against exposure to mucosal microflora and other mucosal antigens and thus play a key 
role in the regulation of mucosal immune responses. Crucial for an efficient barrier 
function are specialized adaptations of the intestine, including tight junctions between 
epithelial cells, secretion of mucus, defensins and immunoglobulin (Ig) A. Intestinal 
epithelial cells can control the uptake, transmission and presentation of antigens through 
a brought set of pathways. Uptake of noninvasive bacteria across the healthy epithelium 
can occur only by active vesicular transport across the epithelial cells or by dendritic 
cells (DC), which actively open the tight junctions between epithelial cells, send 
dendrites outside the epithelium and directly sample bacteria (Rescigno et al., 2001). To 
exclude that the intact epithelial barrier prevents efficient uptake of the E.coli NISSLE-
HA110-120, experiments were repeated under conditions leading to the disruption of the 
epithelium. Dextran sulfate sodium (DSS) is a chemical agent which is known to induce 
colitis in rodents when administrated with the drinking water. DSS-colitis is 
accompanied with activation of non-lymphoid cells such as macrophages and the release 
of pro-inflammatory cytokines. The induction of colitis by DSS has been shown to be a 
T cell independent model for IBD but it is not yet clear if the outcome of colitis 
influences T cell behavior. To be sure that in this system only HA-specific CD4+ T cells 
can act as effector cells in DSS colitis, adoptive transfers of transgenic T cells into T cell 
deficient RAG1-/- mice were done (Fig. 9). 
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Figure 9: Schematic representation of the experimental course.  
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6.5+CD4+ transgenic T cells enriched from spleen and MLN of TCR-HA mice were 
transferred i.p. into RAG1-/- mice and recipients were treated with 6% DSS in the 
drinking water for at least 7 days. At day 3 of DSS treatment the 6.5+CD4+ recipient 
mice were fed with E.coli NISSLE-HA110-120, control bacteria or PBS. Loss of body 
weight was measured during the DSS treatment to follow up colitis induction. In 
contrast to untreated control mice, all DSS treated mice lost 25% of their weight within 
7 days of DSS treatment independent of the bacterial strain used for colonization. (Fig. 
10).  
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After one week of DSS treatment spleen, MLN, LPL
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 Figure 10: DSS induced colitis in 
RAG1-/- mice. RAG-1-/- mice were 
injected i.p. with 107 6.5+CD4+
transgenic T cells and treated with 6% 
DSS in the drinking water for 7 days. 
At day 3 recipients were orally 
inoculated with PBS (open circles), 
E.coli NISSLE (closed triangles) or 
E.coli NISSLE-HA110-120 (open 
triangles). Closed circles describe 
mice that did not receive DSS. Disease 
severity was measured daily and is 
expressed in terms of body weight
loss.   and IEL were analyzed by flow 
he different organs (Fig. 11). The 
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mice receiving DSS (1.6 %) or untreated mice (2.3 %). However, as reduction in cell 
number was seen with both, E.coli NISSLE and E.coli NISSLE-HA110-120, it cannot 
be considered as antigen-specific effect. 
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 Figure 11: Distribution of HA-specific CD4+ T cells in RAG1-/- mice after adoptive transfer of 
6.5+CD4+ T cells, DSS treatment and bacterial colonization. RAG1-/- mice were reconstituted with 
6.5+CD4+ T cells, treated with 6 % DSS in the drinking water for a period of 7 days and inoculated at 
day 3 of DSS treatment with PBS, E.coli NISSLE or E.coli NISSLE-HA110-120. After 7 days the mice 
were sacrificed and the percentage of transgenic T cells was measured by flow cytometry in spleen, 
MLN, lamina propria and intestinal epithelium. or further characterization, the activation status of the recovered transgenic T cells was 
nvestigated by CD69 and CD25 measurement in the spleen (Fig. 12A), MLN (Fig. 
2B) and LPL (Fig. 12C).  
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Figure 12: Expression of CD69 and 
CD25 on HA-specific CD4+ T cells
after DSS treatment. RAG1-/- mice 
were reconstituted with 6.5+CD4+ T 
cells, treated with 6 % DSS in the 
drinking water for a period of 7 days and 
at day 3 inoculated with PBS, E.coli
NISSLE or E.coli NISSLE-HA110-120. 
After 7 days the mice were sacrificed 
and the 6.5+CD4+ transgenic T cells were 
analyzed for the expression of CD25 and 
CD69. Spleen (A); MLN (B); LPL (C) 
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Analyzing the transgenic T cells in the spleen, no differences in the activation pattern 
could be observed. Comparing the expression patterns of MLN between all DSS treated 
mice and DSS untreated mice revealed that in DSS treated mice there is an increase in 
the amount of CD69-positive 6.5+CD4+ T cells (17.2 %, 15.3 %, 24.8 %) compared to 
untreated mice (9.6 %). This effect was similar for the expression of CD25 on 
transgenic T cells with 29.9 %, 26.1 % and 33.6 % in mice that received DSS in contrast 
to 21.3 % in control mice. Nearly no differences in surface marker expression could be 
found for 6.5+CD4+ transgenic T cells in the lamina propria.  
 
These results suggested that the differences in the percentage of 6.5+CD4+transgenic T 
cells is a consequence of DSS treatment and is not influenced by the bacterial 
expression of the specific T cell antigen in the gut lumen. Changes in the expression 
level of the activation markers on transgenic T cells might be driven by the 
inflammatory environment in the gut due to DSS treatment and seems to be antigen 
unspecific. Thus, even under disease conditions where the barrier function of the 
epithelial layer is destroyed, no effect of bacterial antigen expression in the gut on the 
specific activation of mucosal T cells was observed. 
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4 Discussion 
In nearly all rodent models of colitis studied to date, disease development has been 
associated with the presence of enteric flora. However, in non of these models the 
relevant bacterial antigen has been identified, and it has been difficult to define the 
direct involvement of distinct bacterial species or specific antigens to the onset of 
disease. The lack of identification of either the antigenic targets or T cell specificities 
responsible for disease has compromised efforts to understand the pathogenic 
contribution of the enteric flora. Studies of spontaneous colitis in C3H/He/JBir mice 
have demonstrated a surprisingly selective immune reactivity to the enteric flora and 
have suggested that facultative anaerobes such as E.coli and Salmonella species were 
immune stimulatory organisms (Brandwein et al., 1997). Similarly, Bacteroides spp. 
was a common component of bacterial cocktails that induced colitis in germ-free HLA-
B27 transgenic rats colonized with defined flora (Rath et al., 1996). Heliobacter 
hepaticus has been proposed as a requisite component of the enteric flora in the 
CD45RB transfer and IL-10-/-  colitis model (Cahill et al., 1997; Kullberg et al., 1998), 
although this has been discussed controversially (Dielemann et al., 2000). However, the 
diversity and specificity of the T cell population responsive to these bacteria still needs 
to be defined in these and other IBD models. The major advantage of the study 
described here was the use of a model system for characterization of T cell responses to 
bacterial associated enteric antigens in which the target antigen, the bacterial carrier 
organism, and the TCR specificity are well defined.  
 
One possible way to achieve effective mucosal immune responses is represented by the 
secretion or surface presentation of specific antigens by using systems based on those 
secretory systems which have evolved in pathogens for their own means. A modified 
variant of the AIDA autotransporter (Benz & Schmidt., 1989; Benz & Schmidt, 1992; 
Suhr et al., 1996) was used for the efficient surface presentation of the MHC class II 
HA110-120 epitope by integrating the peptide sequence into an external loop of the core 
structure of the AIDA translocator. A technical impediment of these studies was to find 
a bacterial carrier strain that would stably express the HA110-120-AIDA fusion protein 
in vivo and would stably colonize the intestine of the murine host. Earlier studies have 
shown that it is not easy to obtain long-term colonization with laboratory bacterial 
strains newly introduced into the normal flora (Fairweather et al., 1990). To this end 
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E.coli NISSLE 1917 was chosen as carrier organism, as this strain has been shown to be 
part of the commensal microflora, it is completely apathogenic, it is characterized by its 
excellent colonization properties in the gut and used as probiotic strain in biological 
therapy of intestinal disease in human (Blum et al., 1995; Lodinova-Zadnikove & 
Sonnenborn, 1997). The adoption of AIDA autotransporter extended expression of 
HA110-120 in vivo and a single oral application of transformed E.coli NISSLE to mice 
resulted in a colonization of the mouse gut up to six month. The bacterial surface 
expression of the HA110-120 epitope was demonstrated by immunolabeling 
experiments on bacteria isolated from the feces of colonized mice. Additionally, it could 
be demonstrated that bacteria expressing the HA110-120 epitope could stimulate the 
proliferation of their cognate T cells in vitro as well as in vivo. Thus, the level of 
bacterial HA-110-120 expression was proven to be sufficient to potently induce an 
immunogenic response of HA-specific CD4+ T cells. 
 
The colonization of TCR-HA mice with E.coli NISSLE expressing the HA110-120 
epitope or the transfer of naïve 6.5+CD4+ into BALB/c and RAG1-/- mice colonized with 
HA110-120 expressing E.coli NISSLE did not result in the induction of a mucosal 
immune response. In contrast, recent studies implicated, that the reconstitution of SCID 
and BALB/c mice with naïve CD4+ T cells specific to OVA and colonization of these 
mice with OVA expressing E.coli induced wasting disease (Yoshida et al., 2001 
Yoshida et al., 2002). Consistent with the results obtained in the TCR-HA/E.coli 
NISSLE-HA110-120 model, Iqbal et al. (2002) published a colitis model based on the 
use of OVA-producing E.coli and the transfer of TH1 or TH2 OVA-specific CD4+ T cells 
into RAG2-/- mice. By the transfer of naïve OVA-specific CD4+ T cells no colitis was 
observed. The reason for the lack of immune response in recipients of naïve HA-specific 
T cells colonized with E.coli NISSLE-HA110-120 is not yet clear, as Yoshida et al. 
(2001) could demonstrate activation of T cells and induction of intestinal inflammation 
in the OVA-system. Differences in the protocol used could be a reason for the different 
outcome of the experimental results. Yoshida et al. (2001) used SCID mice instead of 
RAG1-/- mice as recipients and the number of transferred T cells (107) was comparably 
high. Naïve T cells need a certain antigen threshold for the induction of an immune 
response against specific antigen. To exclude that the antigenic yield produced by E.coli 
NISSLE-HA110-120 in the gut of recipient mice was too low to activate naïve T cells, 
in vitro activated 6.5+CD4+ T cells were adoptively transferred into colonized BALB/c 
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mice to abate the stimulus threshold. However, also activated transgenic T cells with an 
abated antigen threshold were not able to respond to the luminal bacterial associated 
antigen, neither with clonal expansion nor with changes in the activation pattern of the 
6.5+CD4+ T cells (Fig. 7).  
 
Several mechanisms contribute to the ability of the gut to either react or remain tolerant 
to antigen present in the intestinal lumen. The epithelial cells form a barrier against 
exposure to mucosal microflora and other mucosal antigens. The internalization of 
dietary antigens appears to be widespread throughout the intestinal epithelium, and is 
carried out by epithelial cells (Mowat & Viney, 1997), whereas the uptake of bacteria 
mainly occurs in the Peyer’s patches, via M cells (Neutra et al.,1996). Although only 
invasive bacteria can efficiently induce their own phagocytosis through M cells, 
noninvasive bacteria have been shown to enter the epithelium by active vesicular 
transport across the epithelial cells or by denditric cells which open the tight junctions 
between epithelial cells, send dendrites outside the epithelium and directly sample 
bacteria from the gut lumen (Rescigno et al., 2001). However, these mechanisms of 
bacterial uptake are rather inefficient. Inefficient transepithelial transport of luminal 
bacteria could be the reason for unresponsiveness against bacterial derived HA110-120 
peptide in this described model. Therefore, the epithelium of RAG1-/- mice was 
disrupted by DSS treatment (Okayasi et al., 1990) before oral application of E.coli 
NISSLE-HA110-120. DSS induced tissue disintegration resultes in increased luminal 
bacterial translocation and thereby exposure of the mucosal immune system to bacterial 
associated antigens. All DSS treated RAG1-/- recipients lost about ~ 15 to 25 % of body 
weight within 7 days, indicating an active colitis (Fig. 10). Also changes in the 
percentage and the activation status of transgenic T cells was observed. However, these 
effects were not antigen specific, the differences between the experimental groups 
seemed to be a consequence of DSS treatment and were not influenced by the bacterial 
antigen expression. Furthermore, the application of E.coli NISSLE 1917 did not 
ameliorate the severity of intestinal inflammation, suggesting that this probiotic bacterial 
do not have a positive effect in DSS induced colitis. 
 
One possible reason for the unresponsiveness of T cells against luminal E.coli NISSLE-
HA110-120 could be an organ specific failure to produce the correct T cell epitope 
HA110-120, thereby preventing efficient MHC class II presentation of the antigenic 
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determinant at the surface of antigen presenting cells in the intestine. The uptake of the 
transformed bacteria normally occurs by an active transport into the epithelial cells or by 
dendritic cell, which send dendrites outside the epithelium to sample the bacteria. 
Within the APC bacterial products are degraded in acidic compartments resulting in the 
generation of antigenic peptides. For MHC class I peptides, Kuckelkorn et al. (2002) 
could demonstrate that proteasomes in the small intestine generate a specific set of 
MHC class I restricted epitopes and that proteasomes derived from other organs produce 
a distinct peptide pattern due to their organ-typic subunit composition. They figured out, 
that proteasomal antigen processing could be a further step in the control of organ 
specific immune response. As the processing of E.coli NISSLE-HA110-120 by 
peritoneal macrophages resulted in specific T cell stimulation in vitro and in vivo, it 
might be possible that the kind of MHC class II epitopes generated in the lysomal 
compartments of APC from the peritoneum differ from those in the small intestine. 
 
As different experimental approaches used in this thesis and they all did not result in a 
measurable immune response of HA-specific CD4+ T cells against the bacterially 
expressed specific HA110-120 peptide in the mouse intestine, E.coli NISSLE 1917 
seems to be a useful carrier strain for localized delivery of specific molecules in the 
intestine in cases, where an immune response against the carrier strain and its products 
is undesired. As demonstrated in VILLIN-HA x TCR-HA transgenic mice mucosal 
lymphocytes are able to intervene in an inflammatory process by the production of 
surface molecules or the secretion of cytokines with regulatory properties. To use this 
knowledge of intestinal regulatory mechanism, the scope of E.coli NISSLE 1917 
probiotic action could be extended by genetic modification of these bacteria to deliver 
anti-inflammatory or other biological important molecules to the inflamed mucosa. 
Food-grade Lactocossus lactis has been engineered to secrete IL-10 and was 
therapeutically effective when given intragastrically to mice suffering from IBD 
(Steidler et al., 2000). They had to inoculate the mice daily with a high dose of 
transformed bacteria to ensure intestinal colonization. E.coli NISSLE 1917 colonization 
is efficient to such a degree that one oral application resulted in intestinal colonization 
and stable antigen expression for up to two weeks without further addition of antibiotics. 
Combining the excellent colonization properties and a non immunogenic character, this 
strain is predestinated to be used as a carrier organism for gut focused drug specific 
therapy of IBD. Cost effective localized delivery of a therapeutic agent that is actively 
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synthesized in situ by food-grade bacteria may have potential clinical applications for 
treatment of intestinal inflammation, particularly as an alternative to systemic treatment. 
In principle, this method may also be useful for intestinal delivery of other protein 
therapeutics that are unstable in vivo or difficult/expensive to produce in large 
quantities. 
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5 Summary 
In this study the influence of luminal bacterial antigen on the development of a mucosal 
T cell response in the mouse intestine was investigated. Bacterial autotransporter 
proteins represent an extremely useful system for the efficient surface presentation or 
secretion of heterologous antigens by Gram-negative bacteria in the intestine. A 
modified variant of the AIDA autotransporter was used for the efficient surface 
presentation of influenza virus A/PR/8/34 hemagglutinin (HA) MHC class II epitope 
HA110-120. The antigenic determinant HA110-120 was detectable at the surface of the 
carrier strain E.coli NISSLE 1917. This apathogenic strain is part of the commensal 
microflora of the gut and is characterized by its excellent colonization properties. It 
could be shown that bacterial autodisplay of the antigenic HA110-120 peptide by E.coli 
NISSLE 1917 led to the efficient stimulation of HA110-120 specific T cell proliferation 
in vitro and in vivo. However, following oral application of the NISSLE-HA110-120 to 
TCR-HA mice, in any case, no significant effect of bacterial antigen expression in the 
gut on migration, clonal expansion and the activation status of HA-specific CD4+ T cells 
could be observed. Moreover, the adoptive transfer of naïve and in vitro activated HA-
specific CD4+ T cells into BALB/c and RAG1-/- mice colonized with HA-expressing 
E.coli NISSLE did not induce clonal expansion and had no effect on the activation 
status of HA-specific T cells. Furthermore, DSS treatment of RAG1-/- mice to disturb 
the epithelial barrier before reconstitution with HA-specific CD4+ T cells and 
colonization with E.coli NISSLE-HA110-120, did not result in an effect of bacterial 
antigen expression in the gut on the specific activation of mucosal T cells. Under these 
experimental conditions the mucosal immune system did not respond to the specific 
bacterial associated antigen independent of a healthy or disrupted epithelial barrier. Due 
to the excellent colonization properties of E.coli NISSLE 1917, the complete 
unresponsiveness of T cells against these bacteria, this strain is predestined to be used as 
a carrier organism for gut focused drug specific therapy of IBD. This system will be an 
extremely useful tool for the localized delivery of anti-inflammatory molecules or other 
biological important molecules to the inflamed mucosa.  
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Materials and Methods 
 
1 Mice 
BALB/c mice were obtained from Harlan (Borchen, Germany) and RAG-1-/- mice from 
Jackson (USA). TCR-HA transgenic mice expressing a TCR αβ specific for the peptide 
110-120 from influenza HA presented by I-E d have been described previously (Kirberg 
et al., 1994). VILLIN-HA transgenic animals were generated using a construct 
containing the villin promoter to direct expression of the influenza virus A/PR8/34 
hemagglutinin to epithelial cells along the entire crypt-villus axis (Pinto et al., 1999), a 9 
kB regulatory domain (construct kindly provided by Sylvie Robine, Institut Curie, Paris, 
France) and the complete HA-sequence. Transgene expression was analyzed by PCR 
screening on genomic tail DNA. PCR was performed using a villin specific 5’ primer 
(5’-CCT TAA GCC GGC TGT GAT AG-3’) and a HA specific 3’ primer (5’-TTA CTA 
TTA GAC GGG TGA TGA TGA ATA-3’). RAG1-/-, TCR-HA and VILLIN-HA mice 
were bred in the animal facility at the German Research Centre for Biotechnology. Mice 
aged 12 to 16 weeks were used for experiments which were all performed according to 
National and Institutional Guidelines. Extensive microbial and serological studies were 
performed to exclude the presence of pathogenic bacteria, viruses, fungi and parasites 
which could potentially cause mucosal inflammation in these mice. No pathogens could 
be detected in all clinical samples studied. 
 
 
2 Preparation of lymphocyte populations 
Spleens were rinsed with erythrocyte lysis buffer (Qiagen, Hilden, Germany). 
Mesenteric lymphnodes (MLN) were disaggregated by passing through a 100 µm mesh. 
Cells were washed with FACS buffer (PBS, 2% FCS, 2mM EDTA) and collected by 
centrifugation. LPL were isolated from the small intestine as described (Guy-Grand et 
al., 1978). Briefly, after flushing the gut with PBS, the Peyer’s patches were removed. 
The gut was opened longitudinally and cut into small pieces. Mucus and epithelial layer 
were removed by stirring at 37 °C, first, two times for 10 min in 60 ml of PBS 
containing 3 mM EDTA, then twice for 15 min in 30 ml of Ca-free RPMI containing 
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1% FCS, 1 mM EGTA and 1.5 mM MgCl2. Gut pieces were collected, vortexed for 20 
sec before finely mincing the tissue. Finally LPL were released by enzymatic digestion 
of the gut at 37°C for 90 min in 30 ml RPMI containing 20 % FCS and 100 U/ml 
collagenase. To improve tissue disintegration the suspension was dissociated by 
multiple aspirations through a syringe after 45 min and the end of the incubation. The 
cell suspension was passed through a 100 µm mesh and centrifuged for 10 min at 1200 
rpm. LPLs were collected by density centriguation using a ficoll gradient. 
IEL from the small intestine were isolated as described previously (Guy-Grand et al. 
1978). In brief, Peyer’s patches were removed and, after flushing with PBS, the gut was 
opened longitudinally. The mucosa was scraped off with a scalpel and then dissociated 
by stirring in 50 ml RPMI containing 10 % FCS and dithioerythritol (1 mM) for 15 min 
at 37°C. Cells were collected by centrifugation and the pellet was vortexed for 3 min in 
HANKS medium containing 10% FCS. 2 x 40 ml were rapidly passed through a glass 
wool column (1.5 g packed in a 20 ml syringe; Fisher Scientific), previously 
equilibrated with HANKS/5 mM Hepes. The eluate was collected, centrifuged and cells 
were resuspended in FACS buffer. 
 
 
3 Antibodies and flow cytometry 
The monoclonal antibody 6.5 (α-TCR-HA) was purified from hybridoma supernatant 
and was used in fluorescein isothiocyanate (FITC)-labeled or biotinylated form. 
Monoclonal antibodies α-CD4 (GK1.5 and L3T4), α-CD25 (PC61), α -CD45RB (16A), 
α-CD62L (MEL-14), and α-CD69 (H1.2F3) were used as biotin, FITC or phycoerythrin 
(PE) conjugates. PE-streptavidin- or APC-(Allophycocyanin)-streptavidin-conjugates 
were used as secondary reagents (BD Bioscience, San Jose, CA). Two- and three color 
flow cytometry was performed on a FACSCalibur (BD Bioscience). Data were analyzed 
with CellQuestPro software (BD Biosciences). For gene expression profiling 6.5+CD4+ 
T cells were sorted with the MoFlow cells sorter (Cytomation, Fort Collins, CO). 
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4 Carboxyfluorescein diacetate, succinimidyl ester (CFSE) 
labeling of lymphocytes 
Cell suspension were prepared as described above. Cells were washed in RPMI without 
FCS, resuspended at a concentration of 107 lymphocytes / ml and incubated with 2.5 µM 
CFSE (Molecular Probes, Göttingen, Germany) for 8 min at 37 °C. Two volumes of 
FCS were added and cells were incubated for additional 5 min at 37 °C. After CFSE 
labeling the cells were washed twice with PBS to remove excess of CFSE and FCS. 
 
 
5 Adoptive transfer 
For adoptive transfer experiments in BALB/c, RAG1-/- or VILLIN-HA mice, red blood 
cell-depleted splenocytes from TCR-HA mice were enriched by AutoMACS using the 
CD4+ T cell Isolation Kit (MACS, Miltenyi Biotec, Bergisch Gladbach, Germany) 
following the manufacturers instructions. In case CD25+ cells should be depleted from 
the CD4+ T cell population, biotinylated α-CD25 antibody was added to the biotin 
antibody cocktail of the CD4+ T cell Isolation Kit. The percentage of 6.5+CD4+T cells 
was determined by flow cytometry analysis as described above. Enriched transgenic 
cells, either unlabeled or CFSE labeled, were injected (i.p.) into age and sex matched 
BALB/c, RAG1-/- or VILLIN-HA mice. 
For transfer of activated transgenic T cells splenocytes isolated from TCR-HA mice 
were stimulated in vitro with 10 µg/ml HA110-120 peptide and cultured for 4 days. 
Dead cells were removed by ficoll gradient and viable cells were cultured for an 
additional day. Flow cytometric analysis were performed to determine the percentage of 
6.5+CD4+ lymphocytes and the activation status of the HA specific CD4+ T cells was 
characterized by staining with α-CD25 and α-CD69. 
 
 
6 Histology 
Mice were sacrificed and the gut was immersion fixed in buffered formalin, embedded 
in paraffin, sectioned at 4 µm thickness and stained with hematoxylin and eosin (H&E). 
Immunohistochemistry for T lymphocytes was performed using the rat-anti-human-CD3 
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antibody clone CD3-12 (Serotec Ltd., Kidlington, UK) at 1:1.600 dilution and the 
avidin-biotin-complex (ABC) method with diaminobenzidin as chromogen. 
Immunohistochemistry sections were counterstained with hematoxylin.  
 
 
7 Proliferation assay 
For antigenic stimulation of 6.5+CD4+ T cells from spleen and MLN 5 x 105 cells were 
plated in 96-well flat-bottom plates in a final volume of 200 µl IMDM-medium 
containing 10 % FCS. Flow cytometry analysis was performed to normalize the number 
of specific 6.5+CD4+ lymphocytes in bulk-cultures. Cell suspensions were incubated in 
the presence or absence of 10µg/ml HA peptide (SSFERFEIFPK) (Hackett et al., 1983) 
at 37°C. 3[H]-thymidine incorporation over the last 15 h of a 48 h culture was measured 
by scintillation counting. In case intestinal lymphocytes were used as responders, 105  
IEL or LPL were cultured with different amounts of the HA peptide and 5 x 105 
irradiated BALB/c splenocytes as feeder cells. Culture supernatants were collected for 
CBA measurement after 48 h and proliferation of the cells was estimated by culturing 
the cells in the presence of 1 µCi 3[H] thymidine per well for additional 16 h.  
 
 
8 Cytokine bead array (CBA) 
Quantification of cytokines in culture supernatants of stimulated versus non stimulated 
lymphocytes (see proliferation assay) was performed using the CBA kit (Becton 
Dickinson Heidelberg, Germany) following the manufacturers recommendations. 
Briefly, polystyrene beads (7.5 µm diameter) stained to 6 different fluorescence 
intensities, which have an emission wavelength of ~650 nm (FL 3), were coupled with 
antibodies to different cytokines contained in the kit. The captured cytokines are then 
detected using six specific antibodies coupled to phycoerythrin (PE), which emits its 
flourescence at ~585 nm (FL 2). Standardized mixtures of all cytokines served as 
internal controls. 50 µl of culture supernatant or cytokine standard were added to a 
mixture of 50 µl each capture antibody-bead reagent and detector antibody-PE reagent, 
respectively. The mixture (150 µl in total) was incubated for 2 hours at room 
temperature. Unbound detector antibody-PE reagent was removed by a single washing 
 
CHAPTER IV  87 
step before data acquisition was performed by flow cytometry using a FACSCalibur. 
Acquired data were analyzed using the Becton Dickinson Cytometric Bead Array 
software. 
 
 
9 DNA microarray hybridization and analysis 
Total RNA from sorted 6.5+ CD4+ T cells was isolated using the RNAeasy kit (Qiagen, 
Hilden, Germany). Quality and integrity of total RNA isolated from 105 sorted T cells 
was assessed by running all samples on an Agilent Technologies 2100 Bioanalyser 
(Agilent Technologies, Waldbronn, Germany). For RNA amplification the first round 
was done according to Affymetrix without biotinylated nucleotides using the Promega 
P1300 RiboMax Kit (Promega, Mannheim, Germany) for T7 amplification. For the 
second round of amplification the precipitated and purified RNA was converted to 
cDNA primed with random hexamers (Pharmacia, Freiburg, Germany). Second strand 
synthesis and probe amplification were done as in the first round with two exceptions: 
an incubation with RNAse H preceeded the first strand synthesis to digest the aRNA, 
and the T7T23V oligo for initiation of the second strand synthesis was used. 12.5 µg 
biotinylated cRNA preparation was fragmented and placed in a hybridization cocktail 
containing four biotinylated hybridization controls (BioB, BioC, BioD, and Cre) as 
recommended by the manufacturer. Samples were hybridized to an identical lot of 
Affymetrix MG-U74Av2 chips for 16 hours. After hybridization, GeneChips were 
washed, stained with streptavidin-PE and read using an Affymetrix GeneChip fluidic 
station scanner. Analysis was done with gene expression software (GeneChip, 
MicroDB, and Data Mining Tool, all Affymetrix). The entire data set of this micro-array 
experiment is in MIAME-format and accessible online under 
www.gbf.de/array/download. 
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10 Generation of the HA110-120 expression plasmid and the 
bacterial strain E.coli NISSLE-HA110-120 
As carrier protein for the MHC class II HA110-120 peptide the AIDA autotransporter 
vector which was kindly provided by M. Alexander Schmidt (University Münster, 
Germany) was used. The plasmid harboring the AIDA autotransporter is an ampicillin 
resistant pBR322 derivate that expresses a recombinant AIDA protein under the control 
of its natural promoter (Benz & Schmidt, 1989). The AIDA encoding sequence was 
modified to remove the native passenger; it consists of signal peptide, a linker region 
incorporating a multiple cloning site, and the entire β-barrel core AIDAc. To internally 
integrate the MHC II 110-120 peptide from influenza HA into the n-terminal AIDAc the 
vector was digested enzymatically with XbaI, dephosphorylated and ligated to the 
double-stranded oligonucleotide sequence of HA110-120 VSSFERFEIFPKESS (5’-
CTA GCC GTG TCA TCA TTC GAA AGA TTC GAA ATA TTT CCC AAA GAA 
AGC TCA-3’). The insertion was confirmed by DNA sequencing. As bacterial antigen 
carrier the E.coli NISSLE 1917 strain was used. Bacteria were kindly provided by 
Florian Gunzer (Hanover Medical School, Hanover, Germany). Bacteria were routinely 
stored with 40% glycerol in Luria-Bertani (LB)-medium at -70°C and grown in LB 
liquid culture or on LB agar plates containing 100µg/ml ampicillin. 
 
 
11 Immunofluorescence  
For immunofluorescence staining, bacteria expressing the HA110-120/AIDA 
autotransporter fusion protein and E.coli NISSLE and control bacteria were cultured at 
37 °C to an OD600 of 0.4. 1 ml of the suspension was centrifuged and the bacterial pellet 
was incubated in 1 % BSA/PBS for blocking unspecific antibody binding. Bacteria were 
washed with PBS, incubated for 1 h at RT with the mouse α-HA110-120 antibody 
CMI1.2. followed by washing twice with PBS. Bacteria were resuspended in 1 ml PBS 
and 25 µl of the suspension were spread and air dried on circular coverslips (15 mm 
diameter). Centrifugation was carried out at 1500 x g for 5 min at 4 °C. Labeled bacteria 
were fixed in 3.7 % paraformaldehyd in PBS for 20 min and afterwards washed two 
times with PBS. The IgG CyTM3 conjugated goat anti mouse secondary antibody 
(Dianovo, Hamburg, Germany) was added and after 1 h incubation at 37°C in a 
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humidified chamber the coverslips were washed with PBS three times. The cover slips 
were subsequently mounted in Fluoprep (bioMérieux, Marcy l’Etoile, France) and 
analyzed using a Zeiss Axiophot microscope. 
 
 
12 Immunogenicity of E.coli NISSLE-HA-110-120 
For in vitro studies peritoneal macrophages from BALB/c were isolated and 2 x 104 
cells/well were cultured over night in antibiotic free medium in 96-well flat-bottom 
plates. Non adherent cells were removed and indicated numbers of viable E.coli 
NISSLE and E.coli NISSLE-HA110-120 were added to the macrophages. After 5 h 4 x 
105 CD19 depleted splenic cells from TCR-HA mice were added in medium containing 
200 µg/ml streptamycin, 200 U/ml penicillin and 100 µg/ml gentamycin to kill to viable 
bacteria. 24 h later proliferative response of HA specific T cells was determined by 
adding 1 µCi of 3[H]-thymidine per well for the final 18 h of the experiment. Thymidine 
incorporation was measured by scintillation counting. 
To measure the capacity of recombinant E.coli expressing HA110-120 peptide to 
stimulate their corresponding HA-specific CD4+ T cells in vivo, the adoptive transfer 
system was used. Cells were prepared from the spleen of TCR-HA mice and HA-
specific T cells were enriched by CD4+ T cell Isolation Kit (MACS, Miltenyi Biotec, 
Bergisch Gladbach, Germany) as described above. The percentage of transgenic T cells 
was measured by Flow cytometry analysis and enriched CD4+ T cells were labeled with 
CFSE before adoptive transfer. BALB/c mice were injected i.p. with 2.5 x 106 CFSE 
labeled transgenic T cells and 24 h later the recipient mice were injected i.p. with either 
PBS, 108  E. coli NISSLE as negative control or 108 E. coli NISSLE-HA110-120. Two 
days later splenocytes and MLN cells were isolated and the proliferation of transgenic T 
cells was measured by loss of CFSE labeling. 
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13 Colonization of mice with the E.coli NISSLE-HA110-120 
Bacterial colonization of the gut was performed by oral application of E.coli NISSLE 
and E.coli NISSLE-HA110-120. To ensure stable colonization for more than one week 
0.3 mg/ml ampicillin were added to the drinking water. Successful colonization was 
checked by plating mouse feces on plates containing 100 µg/ml ampicillin during the 
time of the experiment. 
 
 
14 Induction of colitis 
6.5+CD4+ transgenic T cells enriched from spleen and MLN of TCR-HA mice were 
transferred i.p. into RAG1-/- mice. Recipient mice were fed 6 % (wt/vol) Dextran 
sodium sulfate (DSS) (molecular weight, 40 kDa; ICN Biomedicals Inc., Aurora, Ohio, 
USA) dissolved in water for 7 days to induce acute colitis. At day 3 of DSS treatment 
the 6.5+CD4+ recipient mice were fed with E.coli NISSLE-HA110-120, control bacteria 
or PBS. Loss of body weight was measured during the DSS treatment to follow up 
colitis induction. No mortality was observed during the 7 days of DSS administration.  
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Abbreviations 
 
AICD Activation induced cell death 
AIDA Adhesin involved in diffuse adherence 
APC Antigen presenting cell 
CCL Chemokine ligand 
CCR Chemokine receptor 
CD Cluster of differentiation  
CD Crohn’s disease 
CFSE 5’-Carboxyfluorescein diacetat succinimidylester 
CFU  Colony forming units 
cpm Counts per minute 
CXC Chemokine ligand 
DC Dendritic cell 
DSS Dextran sodium sulfate 
FACS Fluorescence activated cell sorter 
FAE Follicle-associated epithelium 
GALT Gut-associated lymphoid tissue  
HA Hemagglutinin  
HEV High endothelial venules 
i.p. Intraperitonal 
IBD Inflammatory bowel disease 
IEC Intestinal epithelial cell 
IEL Intraepithelial lymphocyte 
IFN Interferon 
Ig Immunoglobulin 
IL Interleukin 
LP Lamina propria 
LPL Lamina propria lymphocyte 
LPS Lipopolysaccharid  
LT Lymphotoxin 
M cell Microfold cell 
MALT Mucosa-associated lymphoid tissue 
MHC Major histocompatibility complex 
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MLN Mesenteric lymph node 
OVA Ovalbumin 
PCR Polymerase chain reaction 
PTG Prostaglandin 
RAG Recombinase activation gene 
SCID Severe combined immunodeficiency  
SED Subepithelial dome 
SP Signal peptide 
TBNS Trinitrobenzene sulfonic acid 
TCR T cell receptor 
TGF Tumor growth factor 
TH cell T helper cell 
TNF Tumor necrosis factor 
Tnfrs Tumor necrosis factor receptor family 
Treg Regulatory T cell 
UC Ulcerative colitis 
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